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Platelets are exquisitely reactive to mechanical forces in disturbed blood flow 
caused by vessel branching, stenosis, and interventional medical devices, leading to life-
threatening clots comprised of platelet aggregates. How forces drive platelet aggregation 
on the molecular level is incompletely understood. Integrins, particularly the platelet-
specific αIIbβ3 (GPIIbIIIa), mediate the gradient shear-induced platelet aggregation not in 
their well-known fully activated form but an intermediate state. This intermediate state can 
be induced by merely mechano-signaling of GPIbα, the receptor that initiates platelet 
rolling on endothelium. Since integrins require the cytoplasmic adaptor molecule, talin, for 
activation and cytoskeletal linkage, elucidating talin’s role is critical to understand this 
process.  
Using stenosis-modeling microfluidics and mouse models that perturb specific 
interactions in the Rap-1-talin-integrin axis, we first demonstrated that talin indeed 
regulates platelet aggregation in disturbed flow and proposed the mechanism that aggregate 
buildup is achieved by membrane-recruited talin providing cytoskeletal linkage to the 
integrins. Our results also suggested that GPIbα-induced GPIIbIIIa maturation to the 
intermediate state requires normal talin-integrin binding.  
To gain mechanistic insights on the molecular level, we used single-cell force 
spectroscopy to characterize the two-dimensional (2D) kinetics of integrin-ligand binding 
with talin perturbations in the presence and absence of force. We found that talin, a 
mechanosensor itself, is particularly important for force-mediated integrin binding without 
prior inside-out activation. The formation of catch bond (force prolonged bond lifetime) 
 xvi 
between the fibrinogen ligand and β3 integrin may be crucial for the “biomechanical” 
platelet aggregation in disturbed flow.  
Lastly, we extended the platelet mechanobiology study to investigate a disease 
known to dysregulate platelets: diabetes. We focused on type I diabetes to reduce metabolic 
confounding factors. Using the stenosis microfluidics to screen patients’ blood, we 
preliminarily concluded that diabetes could amplify platelet aggregation by promoting 
more integrins to the intermediate state, but many other factors including racial heritage 
could cause large variance in patient samples’ responses.   
Overall, we identified talin’s critical role in gradient shear-induced platelet 
aggregation. The biophysics studies offered a clearer understanding of how integrins finely 
tune their kinetics in response to mechanical cues. Our results showed the anti-thrombotic 
potential of specific talin and Rap1 blockade and could inform rational design of novel 







CHAPTER 1. MOTIVATION 
Cardiovascular diseases (CVDs) are the leading cause of death globally. Heart attack 
and stroke alone leads to >15 million global deaths annually (World Health Organization, 
2017, May 17). Despite the aggressive aspirin and clopidogrel dual platelet therapy that 
can lead to bleeding side effects, patients still die from blood clots which are mostly 
comprised of platelet aggregates. Among other reasons, the combinatory treatment showed 
limited efficacy in treating clots that were induced by disturbed flow in vessel branching, 
stenosis, and interventional medical devices (Ajzenberg et al., 2005; Nesbitt et al., 2009; 
Rana, Westein, Niego, & Hagemeyer, 2019; Yong et al., 2011). Multiple studies revealed 
that shear-induced platelet aggregates are hierarchical with a bulky outer shell consisted of 
discoid platelets in low activation state (Jackson, Nesbitt, & Westein, 2009; Stalker et al., 
2013). Platelet integrin GPIIbIIIa is the primary mediator of platelet aggregation. In the 
context of biomechanical aggregation, GPIbα signaling to induce GPIIbIIIa affinity 
maturation is required to form substantial aggregates (Y. Chen et al., 2019; Nesbitt et al., 
2009); since integrin needs its adaptor molecule, talin, to properly function, understanding 
how talin regulates integrin mechanobiology will inform the design of novel therapeutics 
that can target platelet biomechanical pathways. 
Talin is a nexus of both outside-in and inside-out signaling of integrins. As part of 
an ancient scaffolding and signaling machinery, talin was suggested to have emerged 
before integrins (Sebe-Pedros, Roger, Lang, King, & Ruiz-Trillo, 2010), reinforcing its 
“master orchestrator” role of integrin adhesion functionality. Previous studies have shown 
different mutations in talin rendered distinct phenotypical behavior of platelets and the anti-
thrombotic potential of specific blockade of talin (Petrich, Fogelstrand, et al., 2007; 
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Stefanini et al., 2014). These studies elucidated talin’s role in soluble agonist-induced 
integrin activation and paved the way to investigate 1) whether talin participates in 
biomechanical discoid platelet (without prior activation by agonists) aggregation and 2) 
how talin regulates integrin’s response to mechanical cues. It has long been difficult to 
elucidate the significance of talin-mediated integrin affinity changes for integrin-ECM 
interactions (Klapholz & Brown, 2017) due to possible concurrent outside-in activation 
and lack of tools to study affinity (single bond) rather than avidity (multiple bonds and 
clustering). We are equipped with appropriate and effective biophysics tools to interrogate  
how talin fine-tunes integrin 2D kinetics (affinity and off-rate). The crosstalk between 
GPIbα and GPIIbIIIa has long been studied as their functions are tightly connected 
(Savage, Saldivar, & Ruggeri, 1996), but limited to assays that did not separate GPIbα’s 
contribution. We propose to characterize tools that could expand the study mechanistically.  
Diabetes is known to dysregulate platelets, specifically GPIIbIIIa function, and the 
dual antiplatelet therapy was demonstrated even less effective for diabetic patients that 
developed CVDs (Ju et al., 2018). We herein compare platelet aggregation and GPIIbIIIa’s 
response to GPIbα mechano-signaling and force loading of diabetic patients vs non-




CHAPTER 2. BACKGROUND 
2.1 Platelet integrin GPIIbIIIa  
2.1.1 Structure of GPIIbIIIa  
Integrins are a family of adhesion and signalling molecules that can transmit signals 
in both outside-in (from extracellular matrix to cytoplasmic domain) and inside-out (from 
intracellular activity to ectodomain) directions. Like all surface receptors, the integrin 
consists of an ectodomain, transmembrane domains (TMD), and short cytoplasmic 
domains (except for β4 integrins).  Interestingly, their ligand binding domain are away from 
where large conformational changes occur on the α and β legs, making them allosteric 
machines (Hynes, 2002). The α and β subunits in combinations form 24 distinct types of 
known integrins, which can be further classified into aI and aI-less integrins (Hynes, 2002). 
The platelet-unique aIIbb3 integrin, also known as GPIIbIIIa, is an aI-less integrin of ~ 250 
kD. Its ligand-binding domain (LBD) is at the cusp of the α and β subunits, although ligand 
peptides predominantly crosslink to the bI domain (Bennett, 1996; D'Souza, Ginsberg, 
Burke, & Plow, 1990), and it mainly recognizes RGD sequence on ligands such as 




Figure 2.1. Schematic of integrin structure and conformations. 1, 2, and 3 show aI-
less integrin (such as GPIIbIIIa) in bent closed (BC), extended closed (EC), and 
extended open (EO) conformations, respectively. 3 depicts structural components of 
the integrin in its active, high affinity form – fully extended with hybrid domain 
swung out. Adapted from (Luo, Carman, & Springer, 2007). 
Integrins extend from the genu domain upwards when activated (Figure 2.1). There 
are at least five divalent cation binding sites on GPIIbIIIa, some dedicated to Ca2+ (K. 
Zhang & Chen, 2012). Cations such as Mg2+ and Ca2+ keep the integrin’s structural integrity 
and facilitate in its activation or the need to stay quiescent – the mechanisms of the dual-
role remain elusive.  
2.1.2 Function of GPIIbIIIa  
The GPIIbIIIa integrin in platelets is an adhesion and signalling molecule that is 
crucial in hemostasis and thrombosis. It is by far the most abundant integrin on the platelet 
(~80,000 copies). It can be activated via inside-out signalling with soluble agonists such as 
ADP, thromboxane A2 (TxA2), C-reactive protein (CRP), and thrombin, in generally weak 
to strong order. Another platelet-specific surface receptor, GPIbα, can also activate 
GPIIbIIIa when it binds its ligand – A1 domain of vWF – under tension (Y. Chen et al., 
2019; Yap et al., 2002). Integrin activation is a direct consequence of its structural change. 
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Two models have been proposed: Springer’s “switchblade” model describes that integrins 
would extend from the genu up to bind ligand, and Arnaout’s “deadbolt” model suggests 
that integrin extension occurs only after ligand binding (Fan et al., 2016; Moser, Legate, 
Zent, & Fassler, 2009), with the switchblade model being more favourable for the 
GPIIbIIIa integrins. Despite the differences of the proposed models, consensus is that 
conformational changes facilitate ligand binding. The integrin can also initiate outside-in 
signaling when it can bind ligands, although this process is often in parallel with inside-out 
signaling (Shen, Delaney, & Du, 2012). Outside-in signaling, as signified by strong and 
sustained intracellular calcium flux (Nesbitt et al., 2002), often leads to more robust platelet 
adhesion and spreading past the early events of platelet rolling and tumbling at reactive 
endothelial surface.  
2.2 Talin in platelet  
2.2.1 Structure and general function of talin 
Talin is a 270 kD large scaffolding/adaptor protein that interacts primarily with 
integrins and other cytoplasmic molecules such as vinculin and actin. Only talin 1 isoform 
is expressed in hematopoietic cells. Talin 1 consists of a 47 kD N-terminal head domain 
containing four subunits: F0, F1, F2, and F3 (altogether called FERM domain) and a linear 
~220 kD C-terminal rod (Garcia-Alvarez et al., 2003; Moser et al., 2009) (Figure 2.2). The 
F3 subdomain resembles a non-canonical phosphotyrosine-binding (PTB) domain that can 
bind to β-integrin tails to activate integrins. Talin is regarded essential in agonist-driven 
inside-out activation of integrin (Shattil, Kim, & Ginsberg, 2010), but is not the only 
gateway in outside-in activation of integrin that induces platelet spreading, due to the 
feasibility of exogenous activation of integrin by Mn2+ or LIBS antibodies (Shen et al., 
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2013; Tadokoro et al., 2003). However, talin still regulates the outside-in signalling 
(Haling, Monkley, Critchley, & Petrich, 2011), though it and Gα13 seem to bind integrin 
on and off throughout the course of cell ligation (Hynes, 2002; Shen et al., 2013). 
Talin notably has been identified as a tension sensor and mechano-buffer as it 
exhibits the ability to unfold and refold in the rod domain, sense stiffness of the ECM, and 
activate – release from its autoinhibited form – upon applied forces to reveal its cryptic 
vinculin binding sites (Austen et al., 2015; Gingras et al., 2006; Kumar et al., 2016; Yao et 
al., 2016). Talin contains at least three actin binding sites which are all next to vinculin 
binding sites (Hemmings et al., 1996), making it a multi-functional mechanosensing 
adaptor for integrins.  
 
Figure 2.2. Schematic of the structure of talin. Adapted from (Klapholz & Brown, 
2017). 
2.2.2 Interaction between β3 integrins and talin   
Without intracellular or stimulatory cues, talin is mostly in a globular, autoinhibited 
form where head (mostly F3) and rod (mostly R9) domains constitutively interact (Khan 
& Goult, 2019). Structural and fluorescent imaging evidence show that talin F3 domain 
first binds to β3 integrins NPxY motif at the membrane distal region (MDR) and 
subsequently the membrane proximal helix region (MPR), breaking the salt bridge between 
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the α and β legs (R995 and D723 in the case of GPIIbIIIa) that locks the integrin in a low 
affinity state (Roberts & Critchley, 2009; Watanabe et al., 2008; Wegener et al., 2007). 
Both biochemical experiments and molecular dynamics simulations show that the plasma 
membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) will need to bind 
talin to activate integrins (Orlowski et al., 2015; Saltel et al., 2009). Electrostatic 
interactions and steric clash drive this process: PIP2 lipids attract positively charged talin 
FERM domains while repelling the negatively charged talin rod domains to relieve talin’s 
autoinhibitory form (Saltel et al., 2009; Song et al., 2012).  
The W359A (WA) and L325R (LR) mutations disrupt talin binding to two distinct 
sites on the integrin cytoplasmic tail: the MDR NPxY motif and the MPR, respectively 
(Stefanini et al., 2014; Tadokoro et al., 2003). Our current understanding is that talin binds 
to integrin β tail via the MDR (W359 on talin) first, which is the highest-affinity interaction 
between integrin and talin; then talin activates the integrin via the second, weaker 
interaction at the MPR (Moser et al., 2009). The weaker interaction at the MPR (L325 on 
talin) is what made talin “special and unique” in its ability to activate integrins, 
differentiating from other PTB-containing adaptor molecules (such as Dok1 and Numb) 
that do not activate integrins (Wegener et al., 2007). Both the LR and WA mutants have 
been shown to abrogate talin-dependent integrin activation in CHO cells (Garcia-Alvarez 
et al., 2003), but the WA mutant impedes GPIIbIIIa function in human megakaryoblastic 
cell line and murine platelets to a significantly lesser degree (Nakazawa et al., 2013; 
Stefanini et al., 2014).  
2.2.3 Interaction between talin and Rap1  
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In leukocytes, talin membrane recruitment is triggered by the Rap1 effector Rap1 
interacting adaptor molecule (RIAM) that binds the talin rod domain. However, RIAM 
pathway is dispensable for integrin activation in platelets (Stritt et al., 2015). Rap1 has 
direct binding sites on talin F0 (K15, R35) and F1 (K98, R118) domains, where F1 R118 
was found to be more crucial for platelet GPIIbIIIa activation with the lipid binding loop 
on F1 (Bromberger, Zhu, Klapproth, Qin, & Moser, 2019; Lagarrigue et al., 2020). Rap1 
needs to be in its activated GTP- instead of GDP-bound form to bind talin. A schematic is 
provided below (Figure 2.3) for a clearer flow of the process: from left to right are Rap1-
talin and Rap1-talin-integrin tail.  
 
Figure 2.3. Schematic of the Rap1-talin-integrin axis for GPIIbIIIa activation. 
Adapted from (Gingras et al., 2019).  
2.3 Platelet GPIbα 
2.3.1 Structure of GPIbα  
GPIbα is a ~145 kD platelet-specific receptor that is a part of the GPIb-IX-V 
complex, which consists of three other glycoprotein units: GPIbβ, GPIX, and GPV with 
2:4:2:1 ratio (McEwan et al., 2011). GPIbα is covalently linked to two GPIbβs with a 
disulfide bond at the membrane-proximal end of the ectodomain (Calverley, Kavanagh, & 
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Roth, 1998). Its ectodomain comprises a leucine rich repeat domain (LRRD) which 
contains the binding site for the ligand vWF-A1 and a long stalk that connects the TMD 
(W. Zhang et al., 2015). GPIbα is abundantly expressed on the platelet with ~25,000 copies 
(Varga-Szabo, Pleines, & Nieswandt, 2008). 
2.3.2 Binding of GPIbα and vWF-A1  
Through hemodynamic forces, vWF can reveal its cryptic A1 domain to rapidly 
associate and dissociate with GPIbα on platelets with fast kinetics (high on-rate and off-
rate) to initiate slow rolling of platelets on the injured endothelial surface (Schneider et al., 
2007; Yago et al., 2008). Crystal structure of GPIbα in complex with vWF-A1 showed 
both ends of the LRRD on GPIbα, termed β-finger and β-switch, bind to the top and bottom 
of A1, respectively (Dumas et al., 2004). This receptor-ligand pair does not support firm 
adhesion due to the relatively low affinity, but their interaction leads to signalling that can 
upregulate integrin (mostly GPIIbIIIa) affinity to realize platelet arrest and subsequent 
outside-in signalling to feedforward the hemostasis cascade (Y. Chen et al., 2019; Shen et 
al., 2012). In the context of thrombosis, the mechanism is similar, which imposed the 
challenging of developing safe and effective therapeutics that can separate the hemostasis 
from thrombosis pathways. Figure 2.4 shows the mechano-signaling of GPIbα-vWF 
binding under pulling force to activate integrins, in which the cytoplasmic molecules 
involved are mostly unknown. Botrocetin (Bc, or botro) is a snake venom that was found 
to enhance affinity of vWF-A1 to GPIbα, resulting in agglutination (aggregation through 
GPIbα instead of integrins). Kinetic and crystallographic studies showed that Bc reduced 
GPIbα-A1 off-rate by two-fold in both human and mouse complexes without affecting the 
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on-rate by two-step a slide-binding mechanism (Fukuda, Doggett, Laurenzi, Liddington, 
& Diacovo, 2005). Bc binds both GPIbα and vWF-A1. 
 
Figure 2.4. Schematic of mechano-signaling of GPIbα to activate GPIIbIIIa. 
Adapted from (X. F. Zhang & Cheng, 2019). 
2.4 Platelet, adhesion, aggregation, and activation 
In the early stage of hemostasis or some pathological condition where subendothelial 
proteins are exposed, platelets are recruited to the active site. In veins and venules where 
blood flow is relatively slow (< 400 s-1), the initiation of platelet recruitment is mostly 
mediated by GPVI-collagen interaction; in arterioles and arteries where blood flow is faster 
(> 800 s-1), interaction between GPIbα and collagen- and endothelium-bound vWF is the 
first to mediate platelet rolling and adhesion (Nuyttens, Thijs, Deckmyn, & Broos, 2011). 
GPVI and GPIbα can both initiate signalling cascade (with GPVI considered a more potent 
signalling molecule) to activate β1 and β3 integrins to enable platelet arrest and aggregation. 
In pathological conditions where disturbed flow and gradient shear are present, platelets 
can aggregate, which is initiated by GPIbα-vWF binding as well.  
 11 
Platelets can be activated via multiple pathways, which can be generally classified 
into two categories: a “biomechanical” (mechano-) pathway that is initiated by 
mechanosensitive surface glycoproteins (such as GPIbα and GPVI) and a “biochemical” 
pathway that includes soluble agonist-bound G protein-coupled receptor (GPCR) 
signalling (such as thrombin receptors PAR1, PAR4, thromboxane A2 receptor TP, and 
ADP receptors P2Y1, P2Y12). The end results (other than integrin upregulation) of the 
biomechanical pathway are still elusive, while the biochemical pathway leads to much 
more potent response of the platelet, especially with strong agonists such as thrombin: 
integrin activation, cytoskeletal remodelling and degranulation (Kaplan & Jackson, 2011). 
When platelets are fully activated, the α- and dense granules release more agonists, 
inflammatory and clotting factors, P-selectin are expressed on the membrane surface, and 
phosphatidylserine (PS) are exposed (inner leaflet flipped inside-out) by lipid scrambling, 
which will allow more platelets to get activated, leukocytes to interact, and blood 
coagulation factors to be recruited to the platelet surface as part of the coagulation cascade 
(Bevers, Comfurius, & Zwaal, 1983; Rosing et al., 1985). Calcium as a secondary 
messenger plays a central role in both types of pathways. The calcium signals differ in 
intensity and duration depending on the stimuli, and the source is from both cytosolic store 
release and extracellular influx (Varga-Szabo, Braun, & Nieswandt, 2009). 
2.5 Transgenic mouse models used in the force spectroscopy study  




Table 2.1. Phenotypical and mutation efficiency information of mutant mice that 
were used for stenosis aggregation and single-cell studies. 
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CHAPTER 3. MATERIALS AND METHODS 
3.1 Mice  
3.1.1 Mouse strains 
Conditional talin1-deficient mice (Tln1fl/flPf4-Cre+, i.e. talin KO), conditional talin1 
(L325R) mutant (Tln1L325R/flPf4-Cre+) and talin 1 (W359A) mutant mice (Tln1W359A/flPf4-
Cre+), and β3(L746A/L746A) integrin mutant mice along with their controls Tln1fl/flPf4-
Cre–, Tln1fl/wtPf4-Cre+ (WT/fl) and WT/wt (WT) were generously provided by Dr. Brian 
Petrich’s lab housed at Emory University and described previously (Haling et al., 2011; 
Petrich, Fogelstrand, et al., 2007; Petrich, Marchese, et al., 2007; Stefanini et al., 2014). 
CalDAG-GEFI (CalDAG-GEFI-/-), conditional STIM1 KO (STIM1fl/flPf4-Cre+), 
conditional Rap1 KO (Rap1afl/flRap1bfl/flPf4-Cre+), conditional talin1 KO (Tln1fl/flPf4-
Cre+) and the control Pf4-Cre+ (Cre+) mice were generously provided by Dr. Wolfgang 
Bergmeier’s lab housed in University of North Carolina, Chapel Hill and described 
previously (Ahmad et al., 2011; Crittenden et al., 2004; Stefanini et al., 2018). 
IL4Rα/GPIbα-tg (IL4) mice and streptozotocin (STZ)-induced diabetic mice were 
generously provided by Dr. Shaun Jackon’s lab housed in University of Sydney. Talin1 F1 
single mutant (Tln1R118E/R118E) and conditional talin1 F1/F0 double mutant mice 
(Tln1fl/R35E,R118EPf4-Cre+) and their controls Tln1fl/wtPf4-Cre+ and WT/wt mice were 
generously provided by Dr. Mark Ginsberg’s lab housed in animal facilities University of 
California, San Diego. B6 mice (from Jackson Laboratory) were housed at Georgia Tech. 
3.1.2 Mouse handling  
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The breeding and colony maintenance of the mutant mice and their littermate 
controls cited above were handled in the respective institutions. The only procedure of 
handling performed at Georgia Tech was for the STZ-induced diabetic mice. Briefly, B6 
mice received were acclimatized for at least 5 days. Male mice of at least 20 g and 6 weeks 
of age onwards that had been fasted for 6 hours would be converted diabetic by IP injection 
of STZ at a dose of 55mg/kg in 0.5 M sodium citrate buffer made fresh and used within 
one hour 5 times over 5 consecutive days. The goal was to create severely and chronically 
diabetic mice without lateral organ damage that could potentially give rise to platelet 
diabetic phenotype.  
3.2 Reagents 
Mouse monomeric and dimeric A1 were generously provided by Dr. Zaverio 
Ruggeri’s lab (The Scripps Research Institute, La Jolla, CA). Human plasma vWF, 
botrocetin (Bc), antibodies MBC370.2 and SZ22, and clinical integrilin (Eptifibatide) and 
hirudin were generous gifts from Dr. Shaun Jackson’s lab (The University of Sydney, 
Australia). The antibody AP5 was generously provided by Dr. Peter Newman’s lab (Blood 
Center of Wisconsin). The canonical platelet agonist amplification loop blockade (ALB) 
cocktail was made from the following pharmacological inhibitors from Sigma: apyrase 
(0.16 U/ml) to scavenge ADP, MRS2179 (100 µM) to block P2Y1 signalling, 2MeSAMP 
(10 µM) to block P2Y12 activation, and Indomethacin (10 µM) to block TXA2 generation.  
Key commercially available reagents are listed below:  
Name Reagent type Usage Company 
JON/A-PE Fluorescently 
labelled Antibody  






labelled Antibody  












Alexa Fluor 488 
Fluorescently 
labelled Antibody 





Stain the expression of 





Stain the expression of 
murine GPIbα  
Emfret 
Analytics 




PAC-1 (FITC) Fluorescently 
labelled Antibody 









Label MBC370.2, SZ22, 
and AP5 antibodies 
Invitrogen 






Thrombin (α) Enzyme Agonist to platelet Enzyme 
Research 
Laboratories  
ADP Small nucleotide 
molecule 





Pharmaceutical  Anticoagulant USP 
Reference 
Standards 






Gouml 6983 Chemical 
(inhibitor) 
Broad spectrum PKC 
inhibitor 
abcam 
GsMTx-4 Peptide toxin 
(inhibitor) 
































3.3 Blood draw  
3.3.1 Mouse 
Blood draw was described in (Stefanini et al., 2014); briefly, mice were anesthetized 
with ketamine/xylazine mix (150 mg/kg, 15 mg/kg) at the volume ten times the body 
weight (diluted with saline); once completely anesthetized, blood was slowly drawn with 
22-23 G needle into syringe that contained 40 U/ml clexane (low molecular weight heparin) 
to prevent platelet activation via inferior vena cava.  
3.3.2 Human 
For the stenosis microfluidics experiments in Chapter 6, blood was drawn from the 
vein with butterfly syringe to 800 U/ml hirudin in saline (Sydney) or 20 U/ml clexane with 
0.005 U/ml apyrase in modified Hepes Tyrode’s (HT) buffer (134 mM NaCl, 12 mM 
NaHCO3, 2.9 mM KCl, 0.34 mM sodium phosphate monobasic, 5 mM HEPES and 5 mM 
D-glucose, 1% BSA, pH 7.4) (Atlanta, Emory).  
3.4 Cell purification  
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3.4.1 Platelets 
For single cell force spectroscopy experiments, mouse blood after the blood draw 
was supplemented with additional anticoagulants, 0.005 U/ml apyrase and ACD buffer 
(85 mM sodium citrate, 72.9 mM citric acid anhydrous, 110 mM D-glucose and 70 mM 
theophylline, pH 4.6), and transferred to a separation tube supplemented with platelet 
washing buffer (PWB) (4.3 mM K2HPO4, 4.3 mM Na2HPO4, 24.3 mM NaH2PO4, 113 mM 
NaCl, 5.5 mM D-glucose, 10 mM theophylline and 0.5% BSA, pH 6.5). The blood was 
centrifuged at 250 g for 2.5 min with soft brake to separate platelet rich plasma (PRP) from 
rest of the blood components. The PRP was extracted and centrifuged at 1950 g for 1 min. 
the platelet pellet was gently resuspended with PWB supplemented with 0.01 U/ml apyrase 
and 20 U/ml clexane and rested for 5 min before centrifuging again at 1950 g for 1 min. 
the platelet pellet was then resuspended in HT buffer with 1 mM Ca2+ supplemented with 
0.02 U/ml apyrase and placed in a 37 °C water bath for 30 min before use. For activation 
by ADP in BFP, the platelet suspension was incubated with ADP 5 min before experiment; 
for activation by Mn2+ in BFP, the Ca2+ in HT buffer was replaced with 0.5 mM Mn2+. For 
cytochalasin D inhibition, platelets were treated with 10 μM cytochalasin D (or e.q. volume 
DMSO for control which were both ~4,000 x dilution) at 37 °C for 45 min prior to 
experiment. For shearing PRP on cone/plate viscometer, mouse blood after the blood draw 
was supplemented with 0.005 U/ml apyrase and 1 U/ml hirudin and diluted with 1x ACD 
buffer without the theophylline and HT buffer before centrifuging at 250 g for 2.5 min with 
soft brake to separate the PRP. The PRP was diluted further with HT buffer (with 1 mM 
Ca2+ unless specified otherwise) a few folds to achieve ~ 50–200k/μL platelet count, and 
the count was not characterized each time because 20–200k/μL showed similar results as 
previously published (Deng et al., 2016). 
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3.4.2 Red blood cells (RBCs) 
For single cell force spectroscopy experiments, blood collections followed the 
protocol approved by the IRB of Georgia Tech after written informed consent was obtained 
from subjects. ~10 μl of human blood were collected from finger prick and centrifuged to 
isolate the RBCs which were biotinylated by incubating with biotin-PEG3500-NHS 
(JenKem) solution and partially swollen by incubation with nystatin (Sigma-Aldrich). 
Detailed protocol described in (Yunfeng Chen et al., 2015). 
3.5 Stenosis microfluidics  
3.5.1 Fabrication and operation of the stenosis microfluidics devices 
The stenosis device wafer was designed on AutoCad (Figure 3.1) and fabricated at 
the Georgia Tech nanofacility using photolithography with SU-8 photoresist. The devices 
were made from casting PDMS on the wafer, where the feature side were attached to air 
plasma-treated coverslip. The channels were 50 μm thick, 200 μm wide, with two 
symmetrical pillars. Two types of channels were used: 80% and 90% stenosis 
corresponding to the gap between the two pillars that create the stenosis; 20 μm gap means 
the channel is 90% stenosis, and 40 μm gap means 80% stenosis. For the diabetic human 
study in chapter 6, only one pillar with the same geometry as the 80% stenosis was present 
in a 130 μm thick, 100 μm wide channel and the flow rate was set to be 16 μL/min.   
The channel was coated with 100 μg/mL human vWF mixed with 2.5 μg/mL 
botrocetin (Bc) from the outlet for 20+ min, then blocked with 2% BSA for 10+ min from 
the inlet, and then flushing the channel through with HT buffer before starting the 
experiment.  Whole blood from mouse incubated with ALB (1:50 dilution from the cocktail 
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stock) and anti-GPIX-FITC (1:20 dilution) for 10+ min was perfused through the channel 
at 13 μL/min for the 90% stenosis and 18 μL/min for the 80% stenosis for 5 min and the 
flow rates were determined empirically to optimize stable aggregation for the blood from 
WT mice. Confocal was used (with pin hole at maximum opening) to image the DIC and 
fluorescence of the whole perfusion process. The imaging plane was set to be close to cover 
glass on the bottom and adjusted manually for maximum signal-to-noise ratio for the 
fluorescent channel for thresholding purpose in data analysis.  
 
Figure 3.1. CAD drawing with dimensions of the 90% and 80% stenosis region. 
Channel thickness (z-direction, out of plane) is 50 μm. 
For human study in chapter 6, single-pillar channel was used. Human whole blood 
incubated 10+ min with a combination of two specified antibodies (MBC370.2 or AP5, 
with SZ22/P2, 1 μg/ml, labeled with either Alexa fluor 488 or 647 by Zenon labeling 
reagent [Invitrogen]) was perfused through HT buffer-washed channel (no coating or 
blocking) at 16 μL/min to achieve bulk shear rate of 1800 s-1. Confocal was used (with the 
same pin hole opening across samples) to image the DIC and fluorescence of the perfusion. 
The imaging plane was set to be close to cover glass and adjusted manually for maximum 
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signal-to-noise ratio for the fluorescent channel for thresholding purpose in data analysis. 
All whole blood perfusion was driven by a syringe pump (Harvard).  
3.5.2 CFD simulation (done by Yunduo “Charles” Zhao) 
CFD simulations were performed using 354,564 and 359,991 meshing elements for 
the 80% and 90% stenosis channels, respectively. The mass flow rate was defined as: 
𝑄 = #$%&'(
)
,        (1) 
where 𝛾+(s-1) was the bulk shear rate, A (m2) was the cross-sectional area, Dh (m) was the 
hydraulic diameter, and λ was the shape factor of the device’s cross-section. And the 
parameters were given by the following equations.  







        (2) 
3.5.3 Analysis and fitting of the platelet aggregation growth  
All image analyses were performed ImageJ using the program’s default image 
intensity thresholding with stack histogram. GPIX-labeled fluorescent platelet aggregates 
were auto-thresholded with manual checking such that the earliest micro-aggregates were 
included in the analysis with minimal background noise. For the set of experiments using 
talin WA, LR, F1 mutants, β3 LA mutant, and their controls, since the aggregate growth 





 ,  (3) 
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where A reflects the amplitude, or saturation level of the curve, K reflects the rate to reach 
saturation, and N (the Hill coefficient) reflects cooperativity – for this case how much lag 
till the first platelet deposit. The independent variable is t (time). For the set of experiments 
using talin KO, Rap1 KO, CalDAG-GEFI KO, STIM1 KO, and the Cre+ control, the mean 
traces were fitted with linear equation. 
3.6 Cone/plate viscometer-FACS (flow cytometry assay)  
Freshly prepared 50 μL murine PRP was gently mixed with 2.5 μg/mL Bc and 1.25 
μL undiluted JON/A-PE and incubated at 37 °C for 1 min and transferred to the stationary 
plate surface of a CAP2000+ cone/plate viscometer (Brookfield Engineering Laboratories, 
Middleboro, MA, USA). The sample was uniformly sheared at rates ranging from 0 
(stationary control) to 10k s-1 for 2 min at 37 °C, after which the sample was collected and 
fixed with 2% paraformaldehyde (PFA) for 15+ min. The sample was then analysed by 
Accuri C6 flow cytometer (BD Biosciences) after it was diluted 10x with HT buffer.  
3.7 2D Kinetic assays and analyses 
3.7.1 Biomembrane force probe (BFP) force-clamp and rupture assays 
The BFP is a single-cell force spectroscopy and the method in detail was described 
in (Yunfeng Chen et al., 2015). Briefly, the experiment setup of the BFP is shown in Figure 
3.2: a bead coated with ligand of interest (in most cases of the thesis, fibrinogen) is attached 
to the apex of a spherical red blood cell (RBC) via SA-biotin interaction, which acts as an 
ultra-sensitive force transducer and is aspirated by a micropipette. A second pipette holds 
a live platelet (right side) is brought into contact with the bead, allowing binding between 
fibrinogen and GPIIbIIIa under a user-selected compression. The platelet holding pipette 
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will then retract to a predefined nano-scale distance, applying tensile force on the 
interacting molecules. This process is done in repeated cycles to increase the statistical 
power of the experiment.  
 
Figure 3.2. The setup of BFP and schematic of bead-coated ligand interacting with 
the integrin receptor on platelet. Adapted and modified from (Ju et al., 2018). 
The deformation of the RBC tracked by the bead-RBC interface records 1) whether 
a binding event occurred and 2) the bond lifetime under a tensile (clamped) force, with a 
longer lifetime implying stronger binding. Figure 3.3 illustrates the types of events 
recorded – lifetime event shows a bond is formed and lasts certain amount of time, rupture 
event shows the bond dissociated before reaching the set clamp force, and no adhesion 
shows no bond was detected. We could also raise the retraction distance to correspond to 
> 1000 pN that would guarantee to rupture noncovalent bonds to measure rupture forces 
of receptor-ligand of interest. For the lifetime measurement (force clamp), the adhesion 
frequency between the receptor and ligand is kept ~20% to ensure most (~89%) 
interactions are single-bond (B. T. Marshall et al., 2003). The data recording and analysis 
were performed using customized LabView (National Instrument) programs.  
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Figure 3.3. BFP raw data: individual events force over time traces.  
3.7.2 Dual BFP setup  
To probe the crosstalk between GPIbα and GPIIbIIIa, a dual BFP is used instead 
(Ju et al., 2017). A platelet would be subjected to interact with two different ligands: first 
a bead coated with vWF-A1 (GPIbα ligand); once a bond lifetime is formed, the platelet 
would be (within one minute) switched to a second bead coated with fibrinogen (GPIIbIIIa 
ligand), where adhesion frequency would be measured. Details in (Ju et al., 2017).  
 
Figure 3.4. Illustration of the dual BFP process.  
3.7.3 General BFP bead functionalization 
Glass beads (~2μm diameter) were first functionalized with 3-Mercapto- 
propyltrimethoxysilane (MPTMS) to be thiolated. Maleimide-PEG3500-N-
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hydroxysuccinimide (MAL-PEG3500-NHS, JenKem) linker was used to mix with the 
protein of interest (fibrinogen, vWF-A1), enabling the protein to attach to the thiolated 
glass bead surface. Then, streptavidin (SA)−MAL (Sigma) was added to so that the bead 
can be attached to biotinylated RBC.  
3.7.4 Adhesion frequency assay  
The BFP setup can also be used for the adhesion frequency assay, where the adhesion 
frequency of the cell and ligand-coated bead is measured by counting adhesion events over 
50 contact cycles. Longer contact time would increase the probability of adhesion (Chesla, 
Selvaraj, & Zhu, 1998). The contact time vary from 0.1 s, 0.2 s, 0.5 s… all the way till 
adhesion saturation (for mouse GPIIbIIIa and fibrinogen interaction, saturation reached 
within 2 s of contact time, Figure 5.4). Thus, adhesion frequency over contact time can be 
fitted with the equation below assuming single step 1st order reaction (Chesla et al., 1998): 
𝑃K = 1 − exp(−< 𝑛 >) (4) 
and     < 𝑛 >	= 	𝑚U𝑚V𝐴W𝐾KY1 − expZ−𝑘\]]𝑡W_`,     (5)       
where <n> is the average number of bonds per contact, mr the expression level of the 
receptor (GPIIbIIIa) on the platelet, ml the density of coated ligand (Fg) on the bead (both 
can be measured with flow cytometry), Ac the contact area, Ka the 2D affinity (in μm2), koff 
the off-rate (s-1), and tc the contact time. Ac and Ka are lumped together as the effective 2D 
affinity AcKa since they cannot be separated in curve fitting (Chesla et al., 1998). 
3.7.5 Measurement of molecular site density and receptor expression  
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The ml and mr were determined via flow cytometry (FACS). Platelets or beads were 
incubated with fluorescently tagged monoclonal antibody against the molecule of interest 
at 10 μg/ml (or as suggested by product instruction) at room temperature for beads and 
37 °C for platelets for 30 minutes and washed for 2 times – platelets were fixed with 2% 
PFA for 10+ min before washing. The washing buffer for the beads was phosphate buffer 
while for the platelets, the HT buffer. Isotype IgGs were added at equal amount to the 
respective samples. The fluorescence intensities were measured by Accuri C6 flow 
cytometer (BD Biosciences) and compared to standard calibration beads (for PE, FITC, or 
Alexa fluor 488) to determine the fluorescence intensity per cell or bead. The site densities 
were estimated by assuming both the platelet and the bead were spheres with 2 μm diameter.  
3.7.6 Lifetime by force bin analyses  
The lifetime distributions for each force bin can be presented by a survival curve: 
Ln of fraction of measurements with a bond lifetime > the lifetime shown on the x-axis 
(Figure 5.6). For each force bin, the survival frequency can either be fitted to a two-state 
or three-state models that are extension of Bell model (Bell, 1978), by differentiating bonds 
to be fast-, intermediate-, and slow-dissociation species (Wei Chen, Lou, & Zhu, 2011; Ju, 
Dong, Cruz, & Zhu, 2013). The theory is that there exist multiple species of bonds with 
off-rates that all follow the Bell model. The two-state fitting equation is shown below: 
𝑆𝑢𝑟𝑣𝑖𝑣𝑎𝑙	𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 = 𝜔; exp(−𝑘;𝑡m) + 𝜔# exp(−𝑘#𝑡m), (6) 
where 𝜔; + 𝜔# = 1,	and for three-state fitting, equation (7) is used:  
𝑆𝑢𝑟𝑣𝑖𝑣𝑎𝑙	𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 = 𝜔; exp(−𝑘;𝑡m) + 𝜔# exp(−𝑘#𝑡m) + 𝜔p exp(−𝑘p𝑡m),  (7) 
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where 𝜔; + 𝜔# + 𝜔p = 1. 𝑘;, 𝑘#, 𝑎𝑛𝑑	𝑘p are the forced off-rates, and 𝜔;, 𝜔#, 𝑎𝑛𝑑	𝜔p are 
fractions of the short-, long-, and intermediate-lived bonds. For two-state fitting, only two 
species of bonds (or two states of the receptor) are considered.  
3.7.7 Bond memory effect analysis  
Memory index was used to quantify the memory effect of bonds, i.e. how likely is 
another bond to form again after a previous bond formation (Zarnitsyna et al., 2007). The 
memory index can be obtained by calculation or by modelling. The method used for this 
thesis was by calculation using the following equation (Zarnitsyna et al., 2007):  






where Δ𝑝  is the memory index, or the difference between the probability of having 
adhesion in the next contact if the previous contact also resulted in adhesion and the 
probability of having adhesion in the next contact if the previous contact was no adhesion. 
The probabilities were calculated by counting the events of transitioning from no adhesion 
to adhesion and vice versa, and consecutive adhesions or no adhesions; the details were 
explained in (Zarnitsyna et al., 2007). For the data included for this analysis, the inclusion 
criteria are: 1) adhesion frequency higher than 15%, 2) cannot have less than 50 events as 
well less than ten of the 0-1, 1-0 transitions. 
3.8 Statistical analyses  
Methods for statistical analyses were all indicated for each data graph in the caption. 
For significance, N.S. means not significant, * means P < 0.05, ** means P < 0.01, *** 
means P < 0.001, and **** means P < 0.001.  
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CHAPTER 4. TALIN REGULATES DISCOID PLATELET 
AGGREGATION IN DISTURBED FLOW 
Disclaimer: this chapter was made possible with the help of graduate student Sam Ehrlich 
(mentee) to run and provide initial analysis of the stenosis microfluidics experiments, 
graduate student Yunduo (Charles) Zhao’s contribution of the CFD simulation (University 
of Sydney),  the transgenic mice and blood sample collection provided by Dr. Wolfgang 
Bergmeier’s lab (University of North Carolina, Chapel Hill), and the transgenic mice 
provided by Dr. Brian Petrich (Emory University) and Dr. Mark Ginsberg (University of 
California, San Diego).  
4.1 Introduction  
“Biomechanical” platelet aggregation, which was coined to define platelet 
aggregation induced by disturbed flow (Y. Chen et al., 2019), had not been strategically 
studied using mouse models and suitable flow chambers. Most of the previous studies used 
collagen-coated flat channels for whole blood perfusion to examine platelet adhesion and 
aggregation, where the phenotypes of the mouse models were cataloged (Lagarrigue et al., 
2020; Nieswandt et al., 2007; Petrich, Marchese, et al., 2007; Stefanini et al., 2014). 
Despite the importance and relevance to in vivo situations, collagen flow study is not 
mechanistic as a myriad of processes would happen simultaneously: collagen capturing 
plasma vWF, engagement and signaling of vWF receptors (GPIbα, GPIIbIIIa) and collagen 
receptors (GPVI, α2β1), and agonist feed-forward loops amplifying platelet activation 
(Cosemans, Iserbyt, Deckmyn, & Heemskerk, 2008; Kaplan & Jackson, 2011). Thus, tools 
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that can isolate the biomechanical contribution for the aggregation are pressingly needed 
for understanding platelet mechanobiology.  
A microfluidics-based stenosis device elegantly showed change of shear alone drove 
thrombus formation in a seminal paper (Nesbitt et al., 2009). In this study, the agonist 
amplification loop was blocked with a cocktail of inhibitors, and GPIbα and GPIIbIIIa 
emerged to be major initiator and mediator of the process. Similar studies demonstrated 
that gradient shear was more pro-thrombotic than constant, high shear (Goncalves, Nesbitt, 
Yuan, & Jackson, 2005; Nesbitt et al., 2009; Tovar-Lopez et al., 2010). Among other 
reasons, explanations include that the leading end of vWF experiences a different strain 
rate than the trailing end, thus lowering the forces needed to unfold the protein (Rana et 
al., 2019), and that low oscillatory flow is needed for maintaining stable and bulky platelet 
aggregates (Nesbitt et al., 2009). Another study identified GPIIbIIIa rather than GPIbα to 
be the major mechano-receptor that mediated platelet activation in temporal shear gradient 
which also required calcium influx (Goncalves et al., 2005). A stable intermediate affinity 
state of GPIIbIIIa was identified by our lab as a result of shear gradient-induced GPIbα 
mechano-signaling and it mediates the biomechanical thrombus growth (Y. Chen et al., 
2019). The follow-up questions focus on the intracellular molecules participating in the 
crosstalk between GPIbα and GPIIbIIIa. In this chapter of the thesis, we will extend the 
stenosis microfluidics study to a few important mouse models to test their aggregation. 
Talin’s role in rapid biomechanical platelet aggregation was relatively unexplored, 
although its mechanical properties and interactions with vinculin had been well studied in 
the context of focal adhesions and cell migration (Elosegui-Artola et al., 2016; Jiang, 
Giannone, Critchley, Fukumoto, & Sheetz, 2003; Kumar et al., 2016; Margadant et al., 
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2011; Yao et al., 2016). Even though integrin function in fibroblasts and white blood cells 
is distinct from that in platelets (Klapholz & Brown, 2017), talin is a well-conserved major 
mechanosensor that links the integrin to the cytoskeleton. Since talin is the last step of 
integrin inside-out activation, we postulate that talin is involved in GPIbα mechano-
signaling, but whether both MDR and MPR interactions are involved is yet to be specified. 
The contribution of Rap1, immediately upstream of talin, particularly in platelet, is also 
likely significant. Phosphoinositide 3-kinase (PI3K) had been identified as essential for 
shear-dependent platelet firm adhesion and spreading on vWF (Yap et al., 2002). PI3K 
would be an early effector in GPIbα mechano-signaling, as it could directly interact with 
14-3-3ζ which is an adaptor-signaling molecule for GPIbα (Y. Chen, Ruggeri, & Du, 2018). 
However, the study by Yap et al. in 2002 was not done in the discoid platelet aggregation 
in disturbed flow context. We explored calcium signal integrator for platelet activation 
(diacylglycerol, or DAG-regulated guanine nucleotide exchange factor: CalDAG-GEFI), 
which can activate Rap1 (Stefanini & Bergmeier, 2010), and intracellular calcium sensor 
stromal interaction molecule 1 (STIM1) that is more important for pro-coagulant than pro-
adhesive activity  (Ahmad et al., 2011; Lang, Munzer, Gawaz, & Borst, 2013). 
4.2  Results  
4.2.1 Optimization of a stenosis microfluidics technique to study murine platelet 
“biomechanical” aggregation that is mediated by GPIbα-vWF interaction 
We first need to establish a method to evaluate the biomechanical aggregation of 
murine platelets. Unlike human platelets that can aggregate even without any prior coating 
(Brazilek et al., 2017; Nesbitt et al., 2009), murine platelets do not aggregate without prior 
coating nor with murine vWF, monomeric or dimeric A1 (data not shown). Thus, artificial 
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forcing of linkage between vWF and the GPIbα by botrocetin (Bc) was found to be 
necessary to initiate platelet deposition and aggregation, which was recently described 
(Selvadurai et al., 2019). We adapted this coating method and experimental protocol to 
establish consistent formation of platelet aggregates with WT mice in our 50 μm-high 
devices (as opposed to the 100 μm-high in the publication). Due to the fabrication limit of 
soft photolithography at the Georgia Tech nano-facility, and the observation that most 
aggregates form on the bottom (due to gravity) portion of the channel (Brazilek et al., 
2017), we deem the 50 μm-high adaption appropriate. We empirically found the flow rate 
optimal for observing steady platelet aggregation to be 18 μL/min for the 80% and 13 
μL/min for the 90% stenosis channel.  
 
Figure 4.1. CFD simulation: 2D and 3D velocity gradient of the 80% and 90% 
stenosis channels. (A) 2D velocity streamlines for 80% stenosis channel, (B) 2D 
velocity streamlines for 90% stenosis channel, (C) 3D velocity streamlines for 80% 
stenosis channel, (D) 3D velocity streamlines for 90% stenosis channel. Simulations 
and graphs contributed by Yunduo “Charles” Zhao from the University of Sydney.  
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CFD simulation showed the velocity sharply increased right before the stenosis 
(acceleration or contraction zone) and quickly decreased immediately downstream of the 
stenosis (deceleration or expansion zone) for both the 80% and 90% stenosis channels, 
with the 90% having a steeper gradient (Figure 4.1). Platelets would accumulate in the 
expansion zone post-stenosis. CFD simulation found the bulk shear rate to be 3460 s-1 for 
the 80% stenosis and 2500 s-1 for the 90% stenosis channel (Figure 4.2). The 2D image 
(Figure 4.2 A and B) showed streamlines a plane at the mid-point of the z-direction. Peak 
strain rate (1 μm away from the tip of the pillar) was ~54,880 s-1 for the 80% stenosis and 
~112,200 s-1 for the 90% stenosis channel. Shear rate near the pillar tip was mostly around 
15k s-1 for the 80% and 30k s-1 for the 90% stenosis channel. In severe stenosis regions in 
the body, shear rate of up to 400,000 s-1 can be found (D. Kim, Bresette, Liu, & Ku, 2019).  
 
Figure 4.2. CFD simulation: 2D and 3D shear gradient of the 80% and 90% stenosis 
channels. (A) 2D shear rate streamlines for 80% stenosis channel, (B) 2D shear rate 
streamlines for 90% stenosis channel, (C) 3D shear rate streamlines for 80% 
stenosis channel, (D) 3D shear rate streamlines for 90% stenosis channel. 
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Simulations and graphs contributed by Yunduo “Charles” Zhao from the 
University of Sydney. 
4.2.2 Rap1-talin axis is important for biomechanical aggregation of platelets while 
CalDAG-GEFI and STIM1 seem dispensable   
Perfusion of ALB whole blood labelled with platelet receptor-specific fluorophore 
(GPIX antibody-conjugated) through the stenosis channel gives rise to platelet aggregation 
that can be quantified with thresholding (Figure 4.3). Platelets were mostly in discoid shape 
(videos not shown). We plotted the fluorescence area (μm2) over time (s) (mean + SEM), 
shown in Figure 4.4, for both the 80% and 90% stenosis channels. Talin WA mutant, 
integrin β3 LA mutant, talin F1 mutant all showed defective aggregation and generally less 
stable platelet aggregates during the ~5 min aggregation process compared to the WT 
controls. Surprisingly, talin LR mutant did not seem to show any defect (n=2), even though 
in collagen flow chamber, they had the most impaired phenotype similar to talin KO 
(Stefanini et al., 2014). In vivo data in (Stefanini et al., 2014) also showed full protection 
from thrombosis in LR mice. Unfortunately, the difficulty of LR mouse breeding left us no 
chance to repeat the experiment.  
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Figure 4.3. Representative images of the stenosis microfluidics experiment. (A) 
Snapshot of WT platelet aggregation in DIC and confocal fluorescent channel; (B) 
Snapshot at similar running time point of β3 LA mutant platelet aggregation in DIC 
and confocal fluorescent channel. 
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Figure 4.4. Fluorescence area of platelet aggregates in stenosis microfluidics reveals 
defects of talin and integrin β3 mutants. All graphs show mean ± SEM over time 
with sigmoidal line fitting described in methods, and the left side presents results 
from 80% stenosis channels while the right side 90% stenosis channels. (A) WT 
control, talin WA mutant, and integrin b3 LA mutant; (B) WT control and talin F1 
single mutant; (C) WT/fl control and talin LR mutant. Each data trace represents ³ 
4 experiments (most far more than 4); 2 of each type of mouse were used.  
To quantitatively compare the fluorescence traces of each experiment for the mouse 
models, we fitted the mean fluorescence areas (by mouse and channel type) with the Hill 
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equation as most of the traces appeared sigmoidal (lines in Figure 4.4, parameters in Figure 
4.5). The fitted parameters were A, K, and N. A represents the saturation level of the curve, 
and we interpret that the larger the A, the bulkier platelet aggregate is. K reflects the rate 
of growth to reach the saturation, but since for each mouse type, the saturation levels 
largely differ, this parameter cannot truly be used to compare how fast the aggregate grows. 
A better way to compare growth rate is getting the instantaneous rate of change; we plotted 
the first derivative of the curves but found it’s easier to just see from Figure 4.4 which 
mean traces have larger slopes. N represents how “sigmoidal”, or how much lag time 
before the first platelet deposit; the smaller the N, the less lag there is, which would imply 
more pro-thrombotic.  
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Figure 4.5. Fit values of the mean fluorescence area traces show difference of 
mutants in both rate and bulkiness of platelet aggregation. All data display mean 
values with 95% CI. Shown in the graphs are A, K, and N fit values for WT control, 
talin WA mutant, and integrin b3 LA mutant, WT control and talin F1 single 
mutant, and WT/fl control and talin LR mutant. Statistics was performed using 
one-way ANOVA with Tukey’s test. 
The results show WA and LA had much less bulky platelet aggregates compared to 
the WT control, and talin F1 single mutant also barely aggregated at all so the fit with the 
Hill equation was worse. Even though no significant difference was found for N among 
WA, LA, and WT control, the trend was larger Ns for the mutants for both 80% and 90% 
channels compared to WT, which meant more lag time for the mutants. There was no 
difference between the WA and LA mutants. Since both mutations disrupt the same general 
binding site, while WA is on talin, and LA on β3 integrins only, the results from both being 
similar suggests that β3 integrins are the predominant mediator of the biomechanical 
platelet aggregation, and their linkage to the cytoskeleton by talin is critical to maintain the 
aggregate under pathologically high shear. To confirm that the aggregation was initiated 
by GPIbα-vWF binding, channel control experiments were performed using botrocetin-
coating only (sans the human vWF) or with same coating but pre-incubating the blood with 
murine GPIbα inhibitor (Figure 4.7 B), and platelets hardly aggregated at all in those 
conditions. To be more confident about the phenotypical results due to disruption of talin-
integrin or talin-Rap1 interactions, we measured the GPIbα expression level of the LA and 
WA mutants along with their controls on the same day and found no apparent difference 
(Table 4.1). Note that for the comparison purpose, the unit mean fluorescence intensity 
(MFI) was used instead of number of copies because the F/P ratio of the fluorescently-
tagged antibody was not determined.  
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Table 4.1. FACS results show platelets from mutant mice have similar size and 
GPIbα expression level.  




1190 1188 1143 1380 
Platelet size 
(FSC-A) 
99,884 94,607 100,493 96,560 
In search for other potential intracellular mediators, we travelled to University of 
North Carolina Chapel Hill to test other platelet mutants on the stenosis microfluidics. For 
this batch of mice with a different bleeding method (retro-orbital), the platelet aggregation 
generally saturated at a large size, and increased more linearly (Figure 4.6), thus the 
comparison was made with the linearly-fitted slopes of the mean traces. Interestingly, 
CalDAG-GEFI and STIM1 did not show a defect, while talin KO and Rap1 KO did (Figure 
4.7 A). The results reinforced what was observed for the talin mutants, and suggest that the 
mechano-signalling pathway from GPIbα to GPIIbIIIa is a specific pathway that merges 
with other pathways at Rap1 and talin, the common last-step of all agonist-induced inside-
out activation pathways of integrins (Shattil et al., 2010).   
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Figure 4.6. Fluorescence area of platelet aggregates in stenosis microfluidics reveals 
defects of Rap1 KO and talin KO, but not CalDAG-GEFI KO or STIM1 KO. All 
plots are mean ± SEM over time. (A) Traces altogether, (B) Overlay of CalDAG-
GEFI KO and the Cre+ control, (C) Overlay of STIM1 KO and the Cre+ control, 
(D) Overlay of talin KO, Rap1 KO, and the Cre+ control. ³ 2 of each type of mouse 
were used. 
 
Figure 4.7. Fit values of fluorescence area traces show differences of knockouts in 
both rate and bulkiness of platelet aggregation. (A) Comparison of slopes of the 
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linear fits for each trace (yellow, 90% stenosis; gray, 80% stenosis) – two-tailed 
unpaired t-test with Welch’s correction was used for the comparisons. Since the 
80% and 90% stenosis aggregation dynamics looked similar, two stars (**) noted 
with both yellow and gray colors show the significance if considering 80% and 90% 
results together. Single star (*) indicated significance if just considering 90% 
stenosis results. (B) Control experiments with channel coated with only botrocetin 
without vWF (Bc-coating only) or with GPIbα inhibitor-incubated whole blood 
(Anti-GPIbα) show that in these conditions, aggregates barely formed compared to 
the experiments with normal coating and without GPIbα inhibitor (Regular).  
4.2.3 Characterization of a rapid method to test if talin binding to integrin GPIIbIIIa is 
necessary in the crosstalk between GPIbα and the integrin independent of resisting 
shear forces  
Talin has at least two roles when interacting with integrins – activating and 
linking integrin to the cytoskeleton. To elucidate talin’s function in the mechano-
signaling through GPIbα, we want to compare integrin’s affinity state when it can 
normally bind talin versus when it cannot. The stenosis microfluidics is a useful tool for 
platelet functional studies, but not so useful to identify the affinity state of integrins 
because the assay is convoluted with the effect of cytoskeletal linkage. When a defect is 
observed for platelet aggregation for the talin mutant, it is unclear whether platelets not 
being able to withstand shear forces was due to weak cytoskeletal support or the integrin 
affinity state being lower. We needed a method to probe integrin and ended up choosing 
the cone/plate viscometer, or rheometer (Y. Chen et al., 2019; Deng et al., 2016). The 
instrument can uniformly shear platelet mixture or PRP, or even whole blood; after the 
shearing application, one can perform subsequent biochemical assays to study the effect 
of such shear forces using methods such as flow cytometry (Chow, Hellums, Moake, & 
Kroll, 1992; Deng et al., 2016; Quach et al., 2018) and Western blot (Moake, Turner, 
Stathopoulos, Nolasco, & Hellums, 1988; Razdan, Hellums, & Kroll, 1994). This method 
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is modular because one can define the shear rate/shear force, time, and temperature, and 
have the flexibility of performing a variety of concurrent or subsequent assays.  
 
Figure 4.8. Cone/plate shearing experiments show distinct platelet aggregate/ 
agglutinate population. (A) Sample DIC images of platelets after shearing at 10k s-1. 
(B) Sample FACS histograms of platelets stained with JON/A antibody: orange is 
after shearing at 10k s-1 for 2 minutes, and cyan is no shear but just placement on 
the viscometer for the same period of time. The number on the histogram shows 
percentage (%) platelets with positive JON/A staining, where threshold of resting 
platelets is ~2%. (C) Sample forward scatter (FSC, horizontal) and side scatter 
(SSC, vertical) profiles of platelets in resting condition, after thrombin activation for 
5 min, and after shearing with botrocetin for 2 min.  
When the murine platelets were sheared with botrocetin at high speed (up to 10k 
s-1, where platelets in PRP at 37 °C would experience ~ 80–130 dyne/cm2 shear stress if 
assuming PRP has 0.8-1.3 mPa×s viscosity) that corresponds to pathological shear 
condition (Y. Chen et al., 2019; Kesmarky, Kenyeres, Rabai, & Toth, 2008), they form 
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two distinct populations shown on the forward and side scatter (Figure 4.8). One 
population consisted of mostly single platelets, and the other aggregates of tens of 
platelets. From the DIC images, platelets even in aggregates/agglutinates were 
predominantly in discoid shape. The fluorescent channel is for binding of an antibody, 
JON/A-PE, that detects only activated murine integrins. This process is confirmed to be 
driven by GPIbα and vWF binding that is ensured by botrocetin, as for IL4Rα/GPIbα-tg 
(IL4) mice where the extracellular domain of GPIbα is replaced with that of human IL-4 
receptor (Kanaji, Russell, & Ware, 2002), no aggregates nor positive JON/A signal were 
observed (Figure 4.9). The formation of “aggregates” was also mostly agglutination 
mediated only by GPIbα, as integrilin (namely Eptifibatide, a peptide drug that blocks 
GPIIbIIIa binding to ligands) did not diminish the aggregate population, but did abolish 
JON/A signal (because it competes with JON/A binding) (Bergmeier et al., 2002). 
Adding ALB did not change the shear-induced agglutination/aggregation outcome 





Figure 4.9. Platelets from IL4 mice show normal activation by agonist (thrombin) 
but completely abolished agglutination and aggregation. Data from two IL4 mice 
were compared with typical B6 response.  
To establish the baseline and test the validity of this method, we applied a range 
of shear rate on the PRP. Remarkably, a shear dosage-increase leads to a dosage increase 
of JON/A positive signal (thresholding at ~2% baseline) (Figure 4.10 D). This directly 
corresponds to a dosage increase of the percentage of platelets in the aggregate 
population as well (Figure 4.10 Ai - Aviii). Shearing at 10k s-1 with JON/A but without 
Bc did not result in any aggregate population or JON/A signal increase (Figure 4.10 B), 
which aligned with previous finding that both Bc and shear were needed (Deng et al., 
2016; Quach et al., 2018). Shearing with the presence of 0.5 μM GsMTx-4 (inhibitor of 
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cation-selective mechanosensitive channels) generated similar results (APPENDIX E), 
which suggested calcium influx through mechanosensitive channels had minimal 
contribution to this process. Since FACS counts events – be it single platelet or 
aggregates, larger aggregates would inevitably emit more fluorescence, masking the 
effect of true increase of JON/A signal. In other words, it is hard to decipher what 
percentage of integrins are shifted to higher affinity states that can be recognized by 
JON/A. Even though the cone/plate viscometer–FACS method has been used as a major 
tool in an important GPIbα-induced platelet clearance study (Deng et al., 2016), this issue 




Figure 4.10. Mechanical dosage response of platelet agglutination/aggregation. (A) i 
through viii (except for v) are SSC vs FSC plots that show progressively more 
platelets getting into the aggregate population: 100, 500, 1000, 3000, 0 (non-sheared 
control sample), 4000, 8000, 10k s-1. (B) SSC vs FSC profile of sample that was 
sheared at 10k s-1 for the same time duration (2 min) but without botrocetin. (C) 
FL2 (fluorescent channel) vs FSC that shows the difference of JON/A and Leo.F2 as 
FL2. (D) % platelet positively stained with JON/A as a function of shear rate. +Bc 
means botrocetin added, and X means no botrocetin added. Each dot is an 
experiment, and the line represent mean.  
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We needed to provide evidence that the fluorescent signal shift was not all due to 
the increase of event/particle size, but also because more integrins were indeed activated. 
We sheared platelets with a different antibody, Leo.F2 (emfret), that binds integrins of all 
conformations, not just the activated. As expected, the aggregate population also emerged 
along with increase of Leo.F2 signal. Plotting the FSC against the fluorescent channel did 
not provide sufficient information on how different the fluorescent channel and the FSC 
are (Figure 4.10 C), as there are two distinct populations. Another option is to compare 
the two histograms of size and of fluorescence intensity using a q-q- plot.  
 
Figure 4.11. Histograms and q-q plots of fluorescent channels vs FSC show 
distinction between antibody that only recognizes activated integrins and antibody 
that recognizes integrins of all conformations. (A) Histograms JON/A-PE and FSC, 
(B) q-q plot of JON/A-PE and FSC: gray dots, and red linear line, (C) Histograms of 
Leo.F2-PE and FSC, (D) q-q plot of Leo.F2-PE and FSC: brown dots, and black 
linear line. Each event/particle is counted as a quantile. 
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An overlay plot of the histograms and a q-q plot (each particle/event as a quantile) 
show that the JON/A channel is indeed different than the FSC: the histograms are 
visually dissimilar (Figure 4.11 A), and the q-q plot does not fit well on the linear line 
(Figure 4.11 B) (the more similar two histograms are, the more linear the q-q plot would 
be (Gibbons & Chakraborti, 2014; WILK & GNANADESIKAN, 1968)).  
 
Figure 4.12. Histograms and q-q plots of fluorescent channels vs FSC show that in 
the presence dimeric A1 instead of botrocetin, the fluorescent channel and FSC are 
very similar. (A) Histograms JON/A-PE and FSC in the presence of dimeric A1 
without botrocetin; (B) q-q plot of JON/A-PE and FSC in such condition: gray dots, 
and red linear line.  
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To note, we do not care much about the lower quantiles (left of the q-q plot and 
low-value population on the histogram) because these are the single-platelet population. 
The higher quantiles are the aggregates that formed upon shearing with vWF-GPIbα 
pulling, which are the focus of the study. In contrast, Leo.F2 and FSC histograms visually 
overlapped well, and the q-q plot fitted much better with a linear line (Figure 4.11 C, D). 
This analysis was done on > three independent experiments and all reached similar 
conclusions (APPENDIX C). The results suggest that the JON/A signal shift was only 
partially due to the increase of particle size, and thus the cone/plate-FACS method can 
still be promising for studying mechano-signaling, though in a semi-quantitative fashion. 
Additionally, shearing washed platelets with dimeric A1 (without botrocetin) generated 
JON/A histogram similar to that of FSC and a linear q-q plot (Figure 4.12), confirming 
that both botrocetin and shear are required for signaling and detectable integrin activation 
in this experimental condition.  
 
Figure 4.13. Percentage of platelet stained positive for JON/A are lower for the β3 
LA mutant than for the WT control. Data presents mean with whiskers marking 
min to max. Statistics was performed using two-tailed unpaired t-test (n > 4). 
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Using this method, we sheared PRP from both β3 LA mutant and the WT ctrl mice 
and found the % platelet positive for JON/A signal was less for the LA mut (Figure 4.13). 
However, the result does not equate % less integrins were in active form for the LA mut, 
as the extend of agglutination (size) could also vary based on mouse condition – age, 
stress, and other factors. The result could be interpreted as such: if β3 tail-talin linkage is 
impaired, less integrins may be activated through the pulling of GPIbα with vWF.  
 
Figure 4.14. Dual BFP results suggest talin WA mutant has impaired integrin 
activation through GPIbα mechano-signaling.  (A) Unpaired comparison (two-
tailed, unpaired t-test with Welch’s correction) of baseline binding of integrin with 
fibrinogen (NT), mouse A1-stimulated, and ADP-stimulated (individual points with 
mean ± SEM). (B) Paired comparison of each platelet: adhesion to fibrinogen before 
and after A1 stimulation (two-tailed, paired t-test). Each dot represents one platelet.  
To test the validity of the interpretation, we used a previously established but low 
throughput method: the dual BFP (Y. Chen et al., 2019). First, we tried to test if the 
mouse platelet integrin, like the human counterpart, presents an intermediate affinity state 
that can be induced by A1 stimulation. Although not significant, the trend showed 
potentially graded integrin affinity state: low (NT), intermediate (A1-stimulated), and 
 49 
high (ADP-stimulated) (Figure 4.14 A). The large variation of platelet adhesion in the 
stimulated conditions can attribute to the heterogeneity of platelets (existence of subtypes 
or different level of stimulation) due to age and other intrinsic factors (Blair, Michelson, 
& Frelinger, 2018; Donati, Gupta, & Reviakine, 2016; Jobe, 2017; Jongen, MacArthur, 
Englyst, & West, 2020). For this reason, we decided to use a paired dual-BFP test. Each 
platelet’s baseline binding to fibrinogen was determined first (< 30 contacts to prevent 
activation); after > one-minute resting, the platelet was brought to interact with mouse 
monomeric A1; after a lifetime > 2s was established, the platelet was switched to interact 
with fibrinogen again to determine probability of adhesion. Using this test, WT/fl 
platelets showed a significant increase of adhesiveness to fibrinogen after the A1 
stimulation (P < 0.019), while talin WA did not show the striking effect of A1 binding 
(Figure 4.14 B). The dual BFP and cone/plate results indicated the likely compromised 
integrin affinity maturation triggered by GPIbα-vWF forced binding due to impaired 
talin-integrin linkage.  
4.3 Discussion  
The expansion of platelet aggregation study beyond aggregometry using 
microfluidics as presented in this chapter can greatly advance the field as such methods, 
when paired with appropriate inhibitors, can single out the mechanical-geometrical effect. 
We first discovered that the talin mutation (W359A) that disrupts binding to the integrin 
tail, which was confirmed by disrupting this interaction with an integrin β3 L746A mutant, 
reduced the extent of early-stage platelet aggregation without agonist amplification. The 
results suggest that talin is a crucial regulator of the biomechanical platelet aggregation 
that is driven by disturbed flow. Based on the prior studies on human platelets, the integrins 
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are mostly in the extended-close, intermediate affinity state (Y. Chen et al., 2019). It has 
been reported that talin without other stimuli can induce leukocyte integrin αLβ2 to an 
intermediate affinity state (Lefort et al., 2012; Y. F. Li, Tang, Puan, Law, & Tan, 2007). 
Considering these results together, talin likely mediates the intermediate state that was 
initiated by GPIbα signaling, and without further activation by agonists, the intermediate 
state is stable. Given talin’s importance in integrin inside-out activation through all known 
agonists, its involvement in GPIbα mechano-signaling is not surprising and highlights the 
versatility and complexity of talin function.  
The result from the LR mutant (albeit the need for repeats to confirm) was surprising 
as the platelet adhesion and aggregation on collagen was greatly reduced in both 
physiological and pathological shear rates (Stefanini et al., 2014). However, the same 
mutation for neutrophils had a different narrative: LR neutrophils presented normal P-
selectin-induced slow rolling through LFA-1 (a β2 integrin), in contrast to the WA 
neutrophils with defective slow rolling and chemokine-induced arrest (Yago et al., 2015). 
Functionally, the LR mutation offered protection from renal ischemia-reperfusion injury, 
an inflammatory disorder where neutrophils play a key role. Our results imply that 
cytoskeletal engagement of integrin through talin is sufficient to resist the extremely high 
shear forces, and it indirectly showed that the integrins were not in activated form that 
requires talin MPR interaction. Perhaps the LR mutation is only crucial for soluble agonist-
induced integrin activation and not mechano-binding induced activation that happens at an 
even shorter time scale (sub-seconds). Taken together, we learn that 1) disruption of MPR 
or MDR interactions leads to distinct outcome in different cell systems and diseases 
(thrombosis vs. ischemia-reperfusion), and 2) for platelets, collagen flow chamber assay is 
 51 
a better predictor for thrombosis and hemostasis phenotype of mice compared to our 
aggregation assay through vWF, although it does not offer as much mechanistic insight.  
Non-impaired biomechanical aggregation of CalDAG-GEFI KO platelets was 
unexpected because CalDAG-GEFI was found to be crucial for platelet adhesion and 
aggregation (Stefanini & Bergmeier, 2010; Stefanini, Roden, & Bergmeier, 2009). More 
repeats are needed to confirm the finding, and the most proper control for CalDAG-GEFI 
KO was WT/wt, not Pf4-Cre+ (Cre+) mice. We didn’t test the WT mice due to time and 
resource constraint, but generally Cre+ and WT mice do not show a difference in integrin 
activation (Stefanini et al., 2014). The result suggested diverging pathways of integrin 
activation initiated by soluble weak agonist vs GPIbα pulling, as CalDAG-GEFI KO and 
platelets expressing low levels of CalDAG-GEFI both showed diminished integrin 
activation with ADP stimulation (Piatt et al., 2016). As expected, STIM1 KO did not affect 
the platelet aggregation as STIM1 was previously identified to be dispensable for platelet 
aggregation in both aggregometer and collagen flow chamber assay (Ahmad et al., 2011).  
The involvement of Rap1 is interesting as talin-Rap1 interaction was suggested to 
anchor talin to the plasma membrane so that talin can be well-oriented to activate integrins 
(Goult et al., 2010; Lagarrigue et al., 2020). Perhaps talin need to be recruited to the plasma 
membrane first to have a higher chance of interacting with integrins, or even if they are in 
proximity of the membrane, they need stabilization with both the membrane and actin 
filament to properly modulate integrin function. The cone/plate viscometer and dual BFP 
results implied that not only is cytoskeletal linkage important, GPIIbIIIa needs normal 
talin-integrin binding to mature to a higher affinity. We preliminarily propose the following 
mechanism that could fit the results: talin first needs to be recruited to the plasma 
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membrane by the lipids and Rap1 to be stabilized and properly oriented, and it needs to 
access the integrin tail to link to the cytoskeleton while maintaining the intermediate 
affinity of integrins. How talin and Rap1 were brought to interact in the first place could 
be a result of simultaneous inside-out signaling and mechanosensing. Talin itself is a 
mechanosensor and mechano-buffer that can unfold in response to mechanical pulling 
(Elosegui-Artola et al., 2016; Kumar et al., 2016; Yao et al., 2016). It is also a smart 
molecule that can filter out noise and responds to cyclic mechanical signals (Tapia-Rojo & 
Fernandez, 2020), and could experiences repeated stretching and relaxation by actin flow 
in cell spreading (Margadant et al., 2011). The biomechanical platelet aggregation is likely 
mediated by multiple mechanosensors including talin.  
A puzzling question still remains: what are the intracellular players upstream of Rap1 
and talin for mechano-activation of GPIIbIIIa by GPIbα? Protein kinase C (PKC) could be 
a candidate as agonist-activation studies suggested CalDAG-GEFI and PKC to represent 
separate but synergizing pathways for GPIIbIIIa activation (Cifuni, Wagner, & Bergmeier, 
2008), and for gradient shear-driven platelet aggregation without blocking the agonist 
amplification loop, the P2Y12 ADP receptor, a co-signalling molecule for PKC, was the 
most important (out of P2Y1, and thromboxane A2) for clot accumulation (Brazilek et al., 
2017), even though we did not observe a noticeable difference between perfusion with or 
without ALB for murine platelet aggregation.  
Overall, the results suggest that GPIIbIIIa activation via GPIbα mechano-signaling 
seems to require both Rap1 activation (which recruits talin to the membrane) and talin 
binding to integrin, but not necessarily talin’s activating effect by interactions at the 
membrane proximal region of β3 tail.  
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CHAPTER 5. TALIN FINETUNES FORCE-MEDIATED 
DISCOID PLATELET ADHESION TO INTEGRIN LIGAND 
Disclaimer: this chapter was made possible because of Dr. Brian Petrich’s generous supply 
of the transgenic mice housed at the animal facility at Emory University.  
5.1 Introduction  
It’s clear that talin plays a pivotal role in inside-out activation of integrins via 
biochemical stimulation of GPCRs and mechano-binding of GPIbα. Talin’s function in 
integrin outside-in activation in early time stage is not clearly delineated. Particularly, 
whether talin plays a role in not pre-activated platelets binding to immobilized ligand had 
not been systematically studied. A seminal paper on bidirectional integrin signaling 
showed talin and Gα13 competitively bind to the β3 tail, while Gα13 predominantly controls 
integrin outside-in signaling (Shen et al., 2013). The study mostly focused on outside-in 
signaling after inside-out stimulation. The adhesion assay that emphasized ligand-induced 
integrin activation was performed on a long timescale (one hour), but nevertheless revealed 
the necessity of talin’s presence for this process. We then ask whether talin is involved at 
the very beginning – one single forced interaction of integrin and fibrinogen – and how 
talin’s specific interactions with the integrin and Rap1 could mediate the binding on such 
a short timescale.   
The GPIIbIIIa integrin cannot bind to soluble fibrinogen without activation by 
agonist, manganese ion, or activating antibody. But it knowingly can bind to immobilized 
fibrinogen, even when extension about the αΙΙb genu or swing-out of the β3 hybrid domain 
was locked with engineered disulfide bonds (Blue et al., 2010; Cheng, Li, Negri, & Coller, 
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2013), although preventing hybrid domain swing-out disabled outside-in signaling and 
cytoskeleton reorganization. To note, the integrin is always in some thermodynamic 
equilibrium with all of the conformational/affinity states (Sun, Costell, & Fassler, 2019). 
In majority of the time, integrins are in the bent-closed conformer, and they could engage 
ligand in the ephemeral time they spend in the extended-closed or extended-open 
conformer, although crystallography and EM images have shown bent integrins in complex 
with small RGD ligands as well (Adair et al., 2005; Xiong et al., 2002).  
Since biomechanical platelet aggregation depends on the β3 integrin’s lasting 
engagement with talin (and cytoskeleton),  we propose to interrogate talin’s effect on force-
mediated ligand binding of the integrin. Our preliminary study with flow chamber coated 
with fibrinogen showed promising results: merely increasing the shear rate from 100 to 
400 s-1 greatly reduced stable adhesion of talin WA mutant platelets without agonists’ 
presence, while for the WT/fl control, the number of stably adhered platelets were 
comparable for the two shear rates tested (Figure 5.1). The results implicated talin WA’s 
higher sensitivity to increased flow or weakened ability to withstand forces. In this chapter, 
we present the findings on how integrin-fibrinogen 2D kinetics are altered with 1) absence 
of talin, 2) mutation that decelerates talin-integrin binding, 3) mutation that debilitates talin 
to activate integrins, and 4) mutations that disrupt binding of talin with Rap1.    
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Figure 5.1. Talin WA mutant platelets cannot adhere as well on fibrinogen at higher 
shear rate. Each dot is field of view. Two independent experiments were done for 
talin WA mutant.  
5.2 Results  
5.2.1 Talin regulates the force-mediated off-rate but not 2D effective affinity of integrin-
ligand binding kinetics  
To study the mechanism of talin’s regulation on forced integrin-binding, we 
deployed single-cell force spectroscopy (Figure 3.2). Cycles of impinging platelets 
(without prior activation) to fibrinogen-coated beads and clamping at preset distances that 
allowed integrin-fibrinogen bond formation and dissociation under force yielded lifetime-
force curves that were binned by average force. Since GPIIbIIIa is the most abundant and 
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functionally important integrin on platelet surface with ~80,000 copies per platelet, we 
assume other fibrinogen-binding integrins, namely αvβ3 which has only several hundred 
copies per platelet (>>100 fold less than GPIIbIIIa), contribute a negligible amount of 
formed bonds (Bennett, Berger, & Billings, 2009). Moreover, we have previously found 
for human platelet, adhesion with fibrinogen-coated bead in the presence of the available 
αvβ3 or αIIbβ3 inhibitors yielded ~50 folds less average number of bonds formed with αvβ3 
than that of αIIBβ3 (Y. Chen et al., 2019). 
Negative control with just streptavidin (SA) coated beads exhibited < 3% non-
specific binding. Adhesion frequency was controlled to be ~20% so that most bonds formed 
are single bond.  GPIIbIIIa and fibrinogen forms catch bond (or catch-slip bond), signified 
by prolonged average lifetime as force increases in the lower force regime, and shortened 
average lifetime as force increases in the higher force regime (Figure 5.2 A). The WA 
mutation on talin abolished the catch bond; rather, the force-lifetime relationship became 
a slip bond where the average lifetime monotonically decreased with incrementing force 
(Figure 5.2 A). The LA mutation on the β3 tail gave rise to lifetimes on similar magnitude 
except for perhaps the lowest force bin (Figure 5.2 B). However, statistics show that the 
LA mutant may not exhibit a catch bond with shorter lifetimes, as there did not appear to 
be a difference of lifetimes in the first three (lowest three) force bins. The result from talin 
KO was comparable to the LA (Figure 5.2 D). Talin LR also gave rise to substantially 
shorter lifetimes with the ligand (Figure 5.2 C), but the shape of the force-lifetime curve 
was different from that of talin WA (more details in 5.2.2). Mutations that disrupt talin-
Rap1 interactions (F1 single, and F1/F0 double mutants) also generated shorter lifetimes 
(still no evident catch bonds) on similar scale as the talin-integrin mutants, although the 
WT/fl control had unusually shorter average lifetimes (Figure 5.5 D). Some inconsistency 
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could be attributed to that these mice were shipped from a different lab and the WT/fl 
control was not a black 6 background. Overall, talin KO and mutations that disrupt talin-
integrin or talin-Rap1 binding or talin’s ability to activate the integrin all shortened 
GPIIbIIIa-fibrinogen single-bond lifetimes, which corresponds to higher forced off-rate for 
the KO and mutants.  
 
Figure 5.2. Lifetime vs force curves show weakened integrin-fibrinogen bonds with 
mutation on talin-integrin interactions. (A) Lifetime over force curve of WT, WT/fl, 
and talin WA mutant. (B) Lifetime over force curve of mixed WT and WT/fl and b3 
LA mutant. (C) Lifetime over force curve of mixed WT and WT/fl and talin LR 
mutant. (D) Lifetime over force curve of mixed WT and WT/fl and talin KO. The 
mixed WT, WT/fl curve is shown repeatedly in (B), (C), and (D). Each dot 
represents mean lifetime ± SEM of a force bin; each bin has > 50 events for forces 
below 25 pN.  
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To confirm that weakened bond strength was the main reason for the abolishment 
of the catch bond with the WA mutation, we also used the rupture force assay to record at 
which force level each bond would break by setting the retraction way beyond the force 
the interaction could bear (1000 pN). Histograms comparison showed that WT/fl bonds 
rupture at higher forces compared to the WA bonds that could not maintain the binding 
beyond 45 pN (Figure 5.3).  
 
Figure 5.3. Integrin-ligand bonds of talin WA mutant rupture at lower forces 
compared to the WT control. (A) Histogram of binned rupture forces; Difference of 
the WA and WT/fl histograms is significant by both Mann-Whitney and 
Kolmogorov-Smirnov tests. (B) Accumulative histogram of WA and WT/fl rupture 
forces. 
In contrast, the apparent 2D effective affinity AcKa (free of force loading) obtained 
from fitting the probability of adhesion curve (Figure 5.4 A) are all similar among the 
mutants and the WT/fl control except for talin KO (Figure 5.4 B). Talin KO has the lowest 
and the only different apparent 2D effective affinity. The fitted apparent off-rate koff (also 
free of force loading) were not different among the mouse types. To clarify, the affinity 
and off-rate were  “apparent” because for the cell expression level and bead coating density 
measurement, the true F/P ratios of the GPIIbIIIa and fibrinogen antibodies were unknown, 
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and thus the values were not the true affinity but were an accurate reflection of the relative 
2D effective affinities for comparison purposes. The results show that integrins are just as 
likely to bind immobilized fibrinogen even when one (not all) talin head-integrin tail 
interaction site is disrupted. However, if talin is largely absent, the likelihood of bond 
formation is reduced.  
 
Figure 5.4. 2D effective affinities of talin and b3 mutants do not differ from WT 
control. (A) Adhesion frequency over contact time curve for WT/fl, talin WA, LR 
mutants, talin KO, and b3 LA mutant. The BFP beads for the LR and LA mutant 
experiments were from a different batch than the ones used for the rest. Each data 
point represents ³ 4 pairs of cell-bead. (B) Apparent AcKa (2D effective affinity) 
from fitting of the adhesion frequency curve. (C) Apparent koff from fitting of the 
adhesion frequency curve. All data represent mean ± SEM. Statistics was performed 
using one-way ANOVA with Tukey’s test.  
5.2.2 Cytoskeletal support, stabilization of talin by Rap1, and integrin function all 
contribute to formation of normal GPIIbIIIa-fibrinogen catch bond  
The talin WA and LR mutants exhibited different force-lifetime relationship as LR 
showed a clear catch bond albeit the shorter average lifetimes (Figure 5.5 C). Since L325 
on talin only weakly interact with integrin tail and is not the major binding site to link the 
integrin to cytoskeleton, we then ask: how important is normal linkage of integrin to intact 
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cytoskeleton for integrin binding kinetics? We treated WT platelets with cytochalasin D 
(CytD) which inhibits actin polymerization and found the integrins were not able to form 
catch bond either (Figure 5.5 A). DMSO (which was used to dissolve CytD) -treated WT 
platelets average lifetimes essentially overlapped with those of WT platelets with no 
treatment. The CytD treated platelets appeared to have higher average lifetimes at the lower 
force regime (Figure 5.5 B).  
 
Figure 5.5. Lifetime vs force curves show weakened integrin-fibrinogen bonds with 
mutation on talin-integrin interactions. (A) Lifetime over force curve of WT treated 
with DMSO, WT treated with cytochalasin D that is dissolved in DMSO (CytD), and 
WT control. (B) Overlay of lifetime over force curve of talin WA mutant and WT 
treated with CytD for comparison. (C) Overlay of lifetime over force curve of talin 
WA mutant and talin LR mutant for comparison. (D) Lifetime over force curve of 
talin F1/F0 double mutant, talin F1 single mutant, and WT/fl control; the lifetimes 
of WT/fl in 15 – 20 pN force bin are higher than the F1 and F1/F0 mutants. Two-
tailed unpaired t-test with Welch’s correction was used for comparisons.  
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The results suggest that both normal cytoskeletal support and integrin activatability 
are important for the formation of GPIIbIIIa-fibrinogen catch bond, and the “feedback” of 
cytoskeleton seems instant: upon GPIIbIIIa-fibrinogen engagement, the absence or delay 
of cytoskeleton linkage can affect how long a bond could last. This is remarkable given 
that the platelets are largely quiescent and maintain their discoid shape, and the consensus 
is that talin is in its autoinhibitory form when there is no activation cue.  
5.2.3 The short-, intermediate-, and long-lived bonds of integrins differ by force bin  
To gain additional insight on how the GPIIbIIIa-Fg bonds differ when talin can 
regularly link integrin to the cytoskeleton versus when it cannot, the bond lifetime survival 
frequency of each force bin was plotted (Figure 5.6). For the WT control, the bin with the 
longest average lifetime is around 15 pN (catch regime), which is shown on the survival 
plot; conversely for the WA mutant, the survival frequencies monotonically shift left as 
force increases, signifying the slip bond. The survival frequency can be fitted with one, 
two, or three state exponential decay (Wei Chen et al., 2011), denoting one, two, or three 
species of bonds that can be ranked from slowest to fastest dissociation (off-rate). These 
bonds can also be called short-, intermediate-, and long-lived bonds if there are three states; 
for two-state, there would be relatively a fast and slow bond species. For the WA mutant 
and WT control, the most appropriate fitting was determined with the best fit, starting from 
the simplest (one-state). Figure 5.7 A and E showed representative survival curves (dots) 
of WA and control with 3-state fitting (line). Both koff and fraction of each bond species per 
force bin can be obtained by the fitting (Figure 5.7 B, D, F, H). Figure 5.7 C and G showed 
log of off-rates so that koff of each species can be fitted with a linear line (Bell model).  
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Figure 5.6. Bond lifetime distributions reinforce the difference shown by catch vs 
slip bond of WT control and talin WA mutant. (A) Survival frequency of bond 
lifetimes by force bins of WT control (mixed WT and WT/fl). (B) Survival frequency 
of bond lifetimes by force bins of talin WA mutant. (C) Survival frequency of bond 
lifetimes by force bins of talin WA mutant zoomed to lower lifetimes (5 s cutoff).  
 For talin WA, the fast-, intermediate-, and slow-dissociating bonds all fitted well 
with the Bell model, and the fraction of each species showed that short-lived bonds 
generally decreased, while intermediate- and long-lived bonds generally trended up with 
incrementing force. Moreover, the slowest-dissociating bonds did not appear in the lowest 
force bin and the fastest-dissociating bonds disappeared after 15 pN (three-state model 
cannot fit the data). For the WT control however, the off-rates of mostly three bond species 
could not fit well with the Bell model (Figure 5.7 G). By speculation, the WA may have 
more states than the WT, as there would be the integrin population unable to link to talin, 
and a small amount of leftover unmutated talin could still facilitate the binding.  
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Figure 5.7. Fittings of the bond lifetime distributions imply bond species differ 
between talin WA mutant and WT control. (A – D) are for talin WA mutant. (A) 
Example fitting of bond lifetime survival frequency curve (the 4th force bin chosen, 
3-state fitting). (B) Fitted forced off-rates of fast-, intermediate-, and slow-
dissociation bonds. (C) Log of the off-rates in (B) to show linear fitting, which 
Talin WA mut bin 4 
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corresponds to fitting with the Bell model. (D) Fitted fraction of fast-, intermediate-, 
and slow-dissociation bonds. (E – H) are the same as (A – D) but for the WT control 
(WT, WT/fl mixed). Data with error bars were shown mean ± SEM.  
A two-state model may be the right model for the WT as described by previous 
publications, but for this data set it would be a forced fit for some bins and may require 
additional manipulation of binning and more experiments. Nevertheless, how many states 
GPIIbIIIa possesses is still debatable (Y. Chen et al., 2019; Litvinov et al., 2011; Litvinov, 
Bennett, Weisel, & Shuman, 2005; Litvinov, Shuman, Bennett, & Weisel, 2002). 
5.2.4 On force history: memory effect seems to depend on talin, but not cyclic mechanical 
reinforcement  
Force history – including past bond formation and force loading of the current 
adhesion event – impacts frequency and quality of bonds for receptors such as T cell 
receptors (TCR) and integrins (Yunfeng Chen et al., 2019; Kong et al., 2013; Zarnitsyna 
et al., 2007). Thus, we tested whether defects on talin-integrin linkage can alter the force 
history effects. First, we analysed running frequency of integrin adhesion – as integrins 
supposedly stochastically form bonds with the ligand, we did not see an upward trend in 
adhesion frequency (APPENDIX A), which suggests the platelets were not progressively 
getting activated as they repeatedly experienced bond association and dissociation. The 
Bernoulli sequence (independent and identically distributed) of adhesion events was 
challenged by our lab, where “memory effect” was discovered (Zarnitsyna et al., 2007). 
TCR and human platelet integrin GPIIbIIIa (data not shown) were found to exhibit 
positive memory, meaning a bond formed increases the probability of a subsequent bond 
formation. The memory index was used as a metric for the memory effect: if the index is 
positive, a bond forms would likely increase the probability a subsequent bond formation; 
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if the index is negative, a bond formed would likely inhibit the next bond formation; if 
the index is close to zero, a bond formed would have no impact on future bond formation. 
Remarkably, mouse GPIIbIIIa also exhibited positive memory to fibrinogen, but talin 
WA mutation greatly reduced it (Figure 5.8).   
 
Figure 5.8. Memory index calculations suggest talin WA mutation abrogates the 
integrin-ligand binding memory effect in at least certain adhesion frequency ranges. 
(A) Memory index of talin WA mutant and WT control for 15-31% and 32-55% 
adhesion frequency ranges. Each point represents a platelet. (B) Mean ± SEM of the 
data points in (A); statistics was performed using two-way ANOVA with Bonferroni 
correction.  
A more immediate force history impact comes from the force loading just preceding 
a bond lifetime. Our lab reported the phenomenon “cyclic mechanical reinforcement” 
(CMR) of lifetime lengthening of an integrin following repeated loading and unloading on 
the receptor (Kong et al., 2013) and described it with a kinetic model (Z. Li, Kong, & Zhu, 
2016). Instead of a single distance (corresponding to force) clamp assay demonstrated in 
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Figure 3.3, multiple loading and unloading cycles can be applied to a formed bond, and the 
lifetime can be measured if a bond can survive the multiple loadings (Figure 5.9).  
 
Figure 5.9. Illustration of cyclic mechanical reinforcement (CMR) assay. The left 
depicts a multiple-cycled BFP event; the right shows increase of cycle number pre-
clamp generally raises the lifetime at the clamped force. Adapted from (Z. Li et al., 
2016).  
 We chose 3.5 cycles of cyclical pulling to be applied to integrin-fibrinogen bond to 
amplify the effect of CMR.  Mean lifetime was indeed increased for WT platelets 
particularly near the “catch” region ~15 pN (Figure 5.10 A). Comparing the lifetime 
distributions of CMR and non-CMR bonds, one can see that the longest lifetimes were 
comparable for both conditions (Figure 5.10 B-C). However, if comparing the first slopes 
of the distributions (the most vertical slope), the ones from CMR are larger (less negative), 
which indicates that the majority short to medium lifetimes (< 5s) are generally longer. The 
effect of CMR tended to eliminate very short lifetimes (<0.01 s) instead of rendering very 
long lifetimes, which generally aligned with our previous findings on α5β1 (Kong et al., 
2013). To exclude the possibility that the CMR effect was due to pre-selection of long-
lived bonds because more short-lived bonds may not survive the repeated loading-
unloading process, we quantified the fraction of lifetimes established out of all adhesion 
events for CMR and single force clamp and found no difference (APPENDIX G). For β3 
LA mutant, mean lifetimes, especially at higher force bins also increased with CMR 
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(Figure 5.10 D), albeit being still quite short compared to WT. Disruption of talin head 
binding to integrin did not have a clear impact on the CMR phenomenon.  
 
Figure 5.10. Cyclic mechanical reinforcement (CMR) appears to be a feature of 
integrin mechanobiology that may not involve talin. (A) Comparison of lifetime over 
force of WT with single force clamp or CMR. Lifetime distributions of equivalent 
force bins for single force clamp (B) and CMR (C) for WT. (D) Comparison of 
lifetime over force of b3 LA mutant with single force clamp or CMR. Lifetime 
distributions of equivalent force bins for single force clamp (E) and CMR (F) for b3 
LA mutant. 
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5.2.5 On ADP agonist and manganese ion stimulation: talin WA mutation impacts 
affinity more than force-mediated off-rate 
To provide a more complete view of the role of talin-integrin binding in integrin 
binding to immobilized ligand, we conducted the following activation studies with the WA 
and WT/fl platelets: 1) stimulating platelets with ADP agonist (high dose, 50 μM) for 5 
minutes, and 2) activating integrins with the potent activator Mn2+ (by replacing the normal 
1 mM Ca2+ with 0.5 mM Mn2+ in the chamber buffer) before measuring adhesion frequency 
and lifetimes with fibrinogen on the BFP. 
 
Figure 5.11. Activation of integrin by ADP and manganese ions show talin WA 
mutation impacts affinity more than force-mediated off rate. (A) Adhesion 
frequency (probability of adhesion, Pa) of WT/fl control and talin WA in resting 
condition (Ca2+ rest, with the regular condition 1 mM Ca2+), 50 μM ADP, and 0.5 
mM Mn2+; each point represents a platelet. (B) Bond lifetimes of the same 
conditions as in (A); each point is a lifetime event. Statistics was performed using 
two-tailed, unpaired t-test, except for comparing the lifetimes of WT/fl and WA in 
Ca2+ rest condition where Welch’s correction was applied.   
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Both ADP and Mn2+ stimulations increased the probability of adhesion (Pa) for the 
WT/fl platelets, which was expected (Figure 5.11 A, black). ADP did not increase the Pa 
for talin WA mut platelets, but Mn2+ did (Figure 5.11 A, red). This result was also expected 
because talin WA platelets had impaired spreading on fibrinogen with ADP and defective 
integrin activation even with more potent agonists (Stefanini et al., 2014), and our data 
with β3 LA mutant platelets showed reduced integrin activation upon ADP stimulation 
(APPENDIX D). Mn2+ is an exogenous activator for integrins and had been shown to 
bypass talin for platelet adhesion and spreading on fibrinogen, which involves outside-in 
signaling (Shen et al., 2013). The data suggested that Mn2+ can further increase integrin 
affinity even for the WA mutant, corroborating that the 2D effective affinity is not affected 
by talin’s ability to engage the integrin.  
In contrast, lifetimes from WA platelets stimulated with ADP and Mn2+ both did not 
show an increase compared to the resting state. For WT/fl, no significance was found 
either, but the P values indicated show that there was a much higher probability that ADP 
and Mn2+ prolonged the integrin-fibrinogen lifetimes. To note, Mn2+ treatment increased 
the encounter of tethering when the platelets were impinged and retracted from the Fg bead, 
and those events were not counted due to inaccurate lifetime measurements. It needs to be 
noted that Mn2+ could potentially induce clustering of integrins (Cluzel et al., 2005), which 
made the lifetime measurement difficult as there could be multiple bond dissociations. 
Overall, the lifetime results implied that Mn2+ cannot rescue the bond lifetime defect of 
talin WA, which aligned with our understanding that the cytoplasmic support of talin and 




It is to our surprise that all talin and β3 mutants that disrupt the Rap1-talin-integrin 
axis reduced integrin-fibrinogen bond lifetimes of resting platelets. For each single bond 
event, the only “stimulation” the platelet received was the 15-25 pN impingement of the 
cell with the bead, and the loading of the bond (if one formed) at 500-800 pN/s loading rate 
prior to lifetime measured at the varied clamped forces. Most of the contacts were sub-
seconds to less than two seconds, so talin would need to engage Rap1 and integrin in those 
short time frames. We cannot exclude the possibility that due to the method limitation, 
repeated integrin-ligand engagement resulted in overall longer lifetimes by the WT 
platelets; but this is unlikely as we did not observe progressively longer lifetimes or 
increased probability of adhesion for the WT. Integrin engagement with the ligand could 
have prompted talin to engage. However, adhesion frequency assay showed that talin KO 
still possessed lower 2D effective affinity compared to the WT and other mutants. Two 
possibilities could have precipitated the result: 1) there are still some baseline interactions 
of talin and integrin so that the integrin affinity is higher, and 2) the multiple impingement 
of the cell, loading, and rupture of integrin-Fg bonds primed talin to interact with integrins. 
It is unlikely that baseline affinity of the WT and mutant integrins are higher than those 
from talin KO because staining of integrins on resting platelets with JON/A (activation 
marker) or soluble fibrinogen were all comparable (Stefanini et al., 2014). The results point 
to a likely scenario that just a few impingements of the cell and pulling of the integrins 
could have increase the chance of talin-integrin interactions that could prime integrins to 
bind ligands.  
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Even though the average bond lifetimes of the LR mut are much shorter compared 
to the WT control, the integrin can still form catch bond with Fg (Figure 5.5 C). Relating 
back to the seemingly not defective biomechanical aggregation result, the force clamp 
result implicated how platelets maintain their bond strength through integrins. For the 
biomechanical platelet adhesion and aggregation, linkage to cytoskeleton seems much 
more important than the competence of integrin activation that’s mostly observed in 
agonist stimulation. The catch-slip signature of bonds rather than the length of average 
lifetime had been reported to be the critical factor in receptor function (Wei Chen et al., 
2011; Liu B, 2014; Bryan T Marshall et al., 2003). Receptors usually form slip bond with 
their monoclonal antibodies and have average lifetimes folds higher than those with their 
natural ligands, but the strong binding does not necessarily lead to signalling. Thus, each 
molecular pair has its “norm” of lifetime value, and the “catch” behaviour could evince 
more about the bond strengthening mechanism (Sokurenko, Vogel, & Thomas, 2008). 
Considering the published and our results, it seems that talin W359-β3 L746 interaction is 
critical for integrin mechanobiology while L325-β3 F727 and F730 interactions are more 
important for biochemical activation of integrins.  
The bond lifetime data may reconcile a disagreement between purified system and 
cell system: our previous study using force probe on live platelets showed GPIIbIIIa and 
fibrinogen form catch bond (Y. Chen et al., 2019), but with all purified molecules, the 
Weisel group saw slip bond instead (Litvinov et al., 2011). GPIIbIIIa-fibrinogen catch bond 
formation requires cell environment where talin and Rap1 plays a pivotal role. Remarkably, 
even for a slip bond (talin WA) that would fit well with the Bell model, there still exists 
multiple species of bonds. The mechanism of talin’s recruitment to the plasma membrane 
and integrin tail remains elusive. Rap1-interacting adaptor molecule (RIAM) was found 
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important for integrin activation in other focal adhesion-forming cells but not for platelets 
(Lee, Lim, Puzon-McLaughlin, Shattil, & Ginsberg, 2009; Stritt et al., 2015). A recent 
study demonstrated that talin was the major and perhaps only effector of Rap 1 for platelet 
integrin activation (Lagarrigue et al., 2020), which could explain the lack of RIAM 
function in platelets.  
Our results largely agree with a previous report in which talin KO abrogated the 
biphasic adhesion behaviour between α5β1 and fibronectin in fibroblasts while kindlin KO 
did not but lowered the average rupture force, and that such adhesion requires F-actin 
coupling (Strohmeyer, Bharadwaj, Costell, Fässler, & Müller, 2017). Though in a different 
integrin and cell system, the machinery is likely preserved. The report however, used 
different retraction speeds to measure rupture forces; our experiments measured true 
lifetimes that least manipulated the receptor-ligand interactions (Yunfeng Chen et al., 
2019). Actin retrograde flow is crucial for focal adhesions by aligning and orienting ligand-
engaged integrins through talin (Swaminathan et al., 2017); we found here that even for 
early ligand engagement, actin polymerization plays a role in stabilizing the bond. 
Evidence show LFA-1 integrins on T cells need actin polymerization and myosin 
contraction to induce or stabilize the extended-open conformation for migration and 
immunological synapse formation (Comrie, Babich, & Burkhardt, 2015; Nordenfelt, 
Elliott, & Springer, 2016). In our study, the integrins should be predominantly in bent or 
extended-closed conformations due to the absence of agonist amplification, and intact actin 
flow could stabilize the bond.   
The significance and mechanism of the memory effect have been relatively 
unexplored. Since signalling can be initiated by a single bond which has been demonstrated 
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in a few molecular systems (Ju, Chen, Xue, Du, & Zhu, 2016; Q. J. Li et al., 2004), 
GPIIbIIIa binding with fibrinogen could potentially trigger some level of signalling that 
contribute to the memory effect. Talin-integrin binding appeared important for positive 
feedback of mostly single integrin-ligand bonds (since the adhesion frequency is low). On 
the higher adhesion frequency window, the memory index difference between the talin WA 
mutant and control was diminished. Clustering of integrins may happen when adhesion 
frequency is higher as the bond dissociation is more likely not single, and it might mask 
the memory effect.  
CMR could be an integrin-specific property that may involve other modulators but 
not talin and cytoskeleton linkage. It would be difficult to decouple the mechanosensory of 
talin and integrin as they work in tandem. We cannot exclude the possibility that the cyclic 
loading and unloading (which happened to be in the frequency range that talin was found 
to be responsive to via unfolding (Tapia-Rojo & Fernandez, 2020)) sensitized talin and 
accelerated its binding to integrin despite the mutation. The L746A point mutation only 
decelerates talin-integrin binding nonetheless. Recent study showed that just membrane 
deformation can activate integrins, which is independent of signalling including the talin 
(J. Kim et al., 2020). We argue that there exist multiple pathways to increase the 
adhesiveness of integrins, and the context for each pathway’s contribution needs further 
exploration.  
The Mn2+ activation experiments provided information relating TM domain and 
ectodomain of the integrin during activation. Mn2+ and activating mAb PT25-2 can activate 
integrins to bind soluble ligands even when α and β subunit TM domains were covalently 
clasped (Luo, Springer, & Takagi, 2004). Mn2+ has been reported to increase on-rate and 
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affinity (accessibility) between GPIIbIIIa and fibrinogen but not off-rate, and marginally 
decrease the force-dependent off-rate (Litvinov et al., 2012). Our adhesion and lifetime 
results supported these previous reports and add that if talin cannot normally associate with 
the integrin, it cannot facilitate and maintain the forced bond lifetimes with ECM.  
Overall, given that talin binding to integrin either in the membrane proximal or distal 
region, talin binding to Rap1, and actin polymerization, all could shorten the bond lifetimes 
particularly under forces in the “catch” region, the current paradigm of Rap1-talin-integrin 
axis for integrin-ligand binding may be incomplete. In the sub-second timescale, would 
Rap1 need to be activated to become GTP-bound first, then recruit talin to the membrane 
to interact with integrins? Since there should be no other inside-out activation cues, the 
bond strengthening would be induced by ligand ligation: more of an outside-in fashion. A 
plausible interpretation is that the bond strengthening would require both intact actin 
dynamics and accessibility to Rap1 on the plasma membrane, which could also contribute 









CHAPTER 6. DIABETES IMPACTS BIOMECHANICAL 
PLATELET AGGREGATION  
Disclaimer: this chapter was made possible with the help of Dr. Angela Lee to tirelessly 
obtain patient blood samples at her clinic in the Heart Research Institute and Dr. Arnold 
Ju’s help with bleeding of the diabetic mice at the University of Sydney. The research 
nurses from Dr. Eric Felner’s clinic at the Emory Children’s Center offered their help to 
obtain pediatric samples and undergraduate researcher Jeffrey Butler (mentee) helped run 
the stenosis microfluidics experiments.  
6.1 Introduction  
Diabetes affects ~425 million people globally and the prevalence is growing (statista, 
2019, Sep 12). Cardiovascular complications from atherothrombosis are the primary cause 
of diabetes-related deaths (Emerging Risk Factors et al., 2010; Leon & Maddox, 2015; 
Moreno & Fuster, 2004). Both type I and type II diabetes accelerate CVD development 
largely due to the exaggerated thrombotic response, although the cellular and molecular 
mechanisms remain unclear (Chawla, Chawla, & Jaggi, 2016; Fowler, 2008). Diabetic 
patients are typically less responsive to conventional anti-coagulant and anti-platelet 
therapies that target the biochemical pathways of thrombosis, which further increases the 
risk of morbidity and mortality (Ju et al., 2018). In contrast, GPIIbIIIa antagonists appear 
to work most effectively for diabetic patients with acute coronary syndromes, albeit 
possible bleeding complications, suggesting that dysregulation of GPIIbIIIa in diabetes 
underlies the inflated risk of thrombosis (Lincoff, 2003; Roffi et al., 2001).  
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Atherosclerotic processes may begin during childhood even though CVDs generally 
do not appear in children or adolescents. Subclinical CVD, namely an increase in blood 
vessel intima-media thickness and plaque buildup, is more commonly seen in type I 
diabetic (T1DM) children, adolescents, and adults compared to their age- and sex-matched 
healthy controls (de Ferranti et al., 2014). Some studies showed that T1DM had about a 
10-fold age-adjusted increased risk of CVD, even higher than that observed in patients with 
the insulin resistant, type II diabetes (T2DM) (de Ferranti et al., 2014; Wisinski & Kimple, 
2016). Interestingly, hyperglycemia (higher blood glucose level) only had a weak 
association with CVD occurrence, suggesting other factors such as inflammation and 
oxidative stress may greatly contribute to the escalated CVD risk in T1DM patients 
(Orchard, Costacou, Kretowski, & Nesto, 2006; Wisinski & Kimple, 2016). Clinical data 
suggests that the higher risk of CVD in T1DM patients is at least partially due to platelets, 
independent of endothelium damage, oxidative stress, and other abnormalities that arise 
with aging and obesity (Wisinski & Kimple, 2016). Thus, elucidating how platelets, the 
central effector of thrombosis, are dysregulated in diabetes is crucial for advancing our 
understanding of the pathology of diabetes-induced CVD.  
A recent paradigm-shifting paper by our collaborator showed that diabetes did not 
affect platelet response to soluble agonists; only when shear forces in the flow condition 
and compressive collision of red blood cells were present was there a pronounced 
enhancement of adhesion of diabetic platelets compared to the control (Ju et al., 2018). The 
in vivo study in the paper showed needle-induced flow disturbances in mouse blood vessel 
resulted in larger thrombi in diabetic mice compared to the control, and integrin GPIIbIIIa 
was the major mediator. A possible link with the redox pathway within the platelet was 
identified and with the aid of Network Analysis, the authors narrowed down to a key player, 
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PI3K, which regulated the hyperreactivity of platelet integrin. To follow up on this work, 
we aim to use the stenosis microfluidics with conformation-specific antibodies to probe the 
affinity state of GPIIbIIIa and investigate the involvement of GPIbα in the hyperreactive 
platelet phenotype.    
6.2 Results  
6.2.1 Stenosis microfluidics as a method for assessing thrombotic risk of type 1 diabetic 
patients  
We first sought to see if there was a difference in platelet aggregation in the stenosis 
microfluidics device between samples from diabetic patients and non-diabetic controls. We 
used the stenosis device that has a single pillar, and with 16 μL/min flow rate to reach a 
bulk shear rate of 1800 s-1, the peak shear rate within 5 μm of the pillar apex could reach > 
20k s-1, which were well-characterized previously (Tovar-Lopez et al., 2013). T1DM 
patient and non-diabetic control (all adults) whole blood samples labeled with antibody 
SZ22 that stains GPIIbIIIa integrins of all conformations were individually perfused 
through the channels and the aggregation processes over ~7 min were recorded. With 4-6 
donors and 10 experiments for the diabetic (DM) and control (ctrl), we demonstrated that 
the diabetic platelets aggregates grew faster and reached higher plateau (Figure 6.1). The 
data shown were selected data where some outliers were excluded as some samples did not 
aggregate much and some control samples had exaggerated aggregation possibly due to 
blood draw that lysed RBCs. Overall, the method was not ideal for screening due to the 
sensitivity to the sample preparation and the large variation even within the same sample. 
The recruited patients and volunteers also had a large variation in age, body mass index 
(BMI), cholesterol level and other metabolic indicators, which could complicate the result 
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interpretation. Interestingly, we did not find a correlation between blood glucose level or 
HbA1c level and the extent of aggregation (patients information kept at the Heart Research 
Institute, Sydney), despite not enough patient samples were obtained. The result showed 
that more diabetic samples tended to exhibit exaggerated aggregation compared to the non-
diabetic control group.  
 
Figure 6.1. Platelets from adult diabetic patient samples accumulated at a higher 
rate and formed bulkier aggregates. Results were plotted as fluorescence area in 
pixel number (sufficed for comparison purpose) over time (s). The graphs shown are 
T1DM vs. control (left) and the same plot including a T2DM donor results (right). 
Data are shown mean ± SEM.  
 To examine more mechanistically, we stained the platelets (in the whole blood) 
with a combination of conformation-specific antibody and the SZ22. This would enable us 
to semi-quantify the fraction of integrins in different conformations, using SZ22 as the 
common denominator. The conformation-specific antibody was either MBC370.2 or AP5, 
which recognizes GPIIbIIIa extension or hybrid domain swing-out, respectively (Figure 
6.2). The blood was labeled with either MBC370.2 + SZ22 or AP5 + SZ22 and each 
antibody was labeled with a different fluorophore. We did not use the gold-standard PAC-
1 antibody, which recognizes GPIIbIIIa ligand binding site, because it is a large IgM 
 79 
antibody that did not seem to penetrate the platelet aggregate well during our trial runs 
(completely negative signal).  
 
Figure 6.2. Schematic of conformation-specific antibodies for GPIIbIIIa. Bent-close 
(BC), extended-close (EC), and extended-open (EO) conformations are shown, 
where SZ22 stains all conformations, MBC370.2 stains the extended (closed and 
open), and AP5, similar to the gold-standard PAC-1 antibody, stains the extended 
open, fully activated integrin. Adapted from (Y. Chen et al., 2019). 
We previously published that biomechanical aggregation was mediated by 
GPIIbIIIa in the EC conformer, which was largely MBC370.2-positive and AP5-negative 
(Y. Chen et al., 2019). We still see some AP5 staining but it was overall less than 
MBC370.2, and the ALB treatment did not seem to alter the aggregation dynamics. 
Fluorescence area at the saturation aggregation of each perfusion of MBC370.2 or AP5 
normalized by SZ22 was plotted (Figure 6.3). Comparing the MBC370.2/SZ22 ratio of 
T1DM and control, the DM group displayed higher ratio regardless of the presence of ALB 
(Figure 6.3 B). In contrast, AP5/SZ22 ratio did not show any difference across the 
conditions, implying only the portion of EC integrins was higher for the DM group. 
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Figure 6.3. Fluorescence area ratio of conformation-specific antibody and SZ22 
showed T1DM had more integrins in the extended-close conformation. (A) 
Representative images of the aggregates stained with SZ22 (green) and MBC370.2 
(blue) from T1DM and ctrl samples with or without ALB. (B) Fluorescence area 
(aggregate size) ratio of MBC370.2 over SZ22, comparing the patient samples with 
and without ALB. (C) Fluorescence area (aggregate size) ratio of AP5 over SZ22, 
comparing the patient samples with and without ALB. For (B) and (C), each bar 
represents ³ 3 ratios taken, and one-way ANOVA with Tukey’s test was used.  
Since the variation was large for adult patients, we decided to explore pediatric 
samples and to recruit patients of 8-17 years old. The 80% and 90% symmetrical stenosis 
devices were used to generate to the results (Figure 6.4). The data was segregated by racial 
heritage as each patient’s “norm” of aggregation seemed distinct, and racial information 
was provided and could potentially be important. Figure 6.4 A shows all diabetic sample 
aggregation results (stained by SZ22) and B shows just the results of the Hispanic-native 
American and white patients since these two had very low level of aggregation. The patient 
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information is shown in Table 6.1. Two diabetic samples from black patients were obtained, 
and one sample each for the other racial heritages. Albeit the limited samples, no clear 
trend of aggregation result can be seen with sex, BMI, or HbA1c.  
 
Figure 6.4. Platelet aggregation dynamics differ by patients. (A) T1DM patient 
results altogether, with the type of channel used noted, (B) same graph as (A) but 
only showing results from Hispanic-native American and white patients, (C) results 
from T1DM patient and a non-diabetic sibling in a black family, (D) results from 
T1DM patient and a non-diabetic sibling in a Hispanic-white family. Data are 
shown mean ± SEM with sigmoidal fitting; each data trace has n ³ 2 experiments. 
All data that were collected were presented.  
Since large differences can be seen from patient samples possibly due to their racial 
background among other reasons, we decided to test DM vs control samples from the same 
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household. On the days we could recruit a DM patient with his/her sibling with them, we 
would run both samples. We obtained such results from two different pairs of siblings 
(Figure 6.4 C-D). Albeit the limited samples, both pairs showed similar trends: DM sample 
aggregated faster to reach a higher saturation. To note, for the black family pair, the device 
used for the ctrl was 90% stenosis instead of 80% as for the DM; 90% stenosis channel has 
a steeper shear gradient that could be more activating to platelets (Figure 4.2). thus, the 
difference between the DM and ctrl for the black family pair could be even larger were 
they both run in the same type of channel. Information of the sibling pairs are shown in 
Table 6.1 (shaded rows). Neither BMI nor age had correlation with the extent of 
aggregation by inspection.  
Table 6.1. Information of pediatric patients and sibling controls.  
Patient ID Sex Race Age Diabetic BMI HbA1c (%) 
D-30 F Black 11 Yes 20.9 11.4 
D-33 M Black 10 Yes 34.2 12.9 
C-18 F Black 11 No 43.2  
D-36 M White-Hispanic 13 Yes 16.8 8.1 
C-19 M White-Hispanic 10 No 17.2  
D-35 M White-non-
Hispanic 
12 Yes 19.3 8.8 
D-31 F American Indian 
- Hispanic 




6.2.2 For diabetic platelets, GPIIbIIIa’s response to force loading on itself or through 
GPIbα mechano-signalling seems not dysregulated  
From the stenosis microfluidics results, we were puzzled whether DM platelets 
inherently had more intermediate integrins or the GPIbα mechano-signaling pathway was 
dysregulated. To examine whether GPIIbIIIa affinity maturation through GPIbα signalling 
was altered in DM, we used the cone/plate-FACS method described in section 4.2.3 with 
samples from STZ-induced diabetic mice (mimicking chronic T1DM) and their age- and 
sex-matched littermate control. We added both botrocetin and murine dimeric A1 (though 
the dA1 was later found to not be necessary) to the platelet mix and sheared uniformly at 
10k s-1 for 10 min. Shearing the sample generated the signature second population shown 
in Figure 4.8. Using 0 s-1 for 10 min as thresholding baseline, we obtained the % platelet 
positive and MFI stained by JON/A-PE but found no difference between the DM and ctrl, 
regardless of the presence of botrocetin. As a control experiment, shearing the sample with 
integrilin blockade did not prevent the agglutination (almost identical FSC and SSC) but 
abrogated JON/A-PE signal, as integrilin blocks JON/A access to GPIIbIIIa.  
 
Figure 6.5. Cone/plate viscometer (rheometer) – FACS result showed no difference 
between diabetic and non-diabetic samples. (A) % platelet positive for JON/A-PE 
 84 
signals. (B) Mean fluorescence intensity (MFI) of JON/A-PE. Each dot represents 
one experiment. 
 To further explore whether integrins on diabetic (STZ-induced) mouse platelets 
exhibit altered property that contributed to the hyperreactivity, we subjected them to varied 
force loading and measured succeeding bond lifetimes on the BFP. We chose this method 
to probe the integrins because we previously found that mouse GPIIbIIIa was exquisitely 
sensitive to force loading (Yunfeng Chen et al., 2019). The adhesion frequency was control 
to ~20% to measure mostly single bonds. However, we did not observe an impact of force 
loading rate on lifetimes in the diabetic platelets we tested (Figure 6.6). Even with rate 6x 
higher, the average lifetime or the range of lifetimes did not change. GPIIbIIIa on diabetic 
platelets did not show a response in bond strength to different loading rates; hence we did 
not pursue the same test on the non-diabetic controls.   
 
Figure 6.6. Lifetimes of integrin-fibrinogen bonds in varied force loadings showed 
no difference. Data was obtained from two STZ-induced diabetic mice; each point is 
one lifetime event; the bar shows mean ± SEM (red). X-axis shows binned force 
loading rates, with each rate being the average of that bin.  
6.3 Discussion  
Diabetes’ impact on platelet in shear-induced activation and on the molecular level 
of detail was not examined until our collaborator’s work which was recently published 
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(Ju et al., 2018). We followed up the study by comparing DM and ctrl gradient shear-
induced platelet aggregation and found a trend of amplified aggregation of samples from 
the DM group for both adults (excluding some outliers) and adolescents. The adolescent 
(pediatric) samples may be better for this assay since there were less metabolic 
confounding factors. From the adult DM group, the extension-recognizing antibody 
showed more staining area normalized by the antibody recognizing all conformations of 
GPIIbIIIa, suggesting that the exaggerated aggregation may be due to more integrins in 
the intermediate affinity state. How the integrins got promoted to that affinity state was 
unclear – they could have been constitutively more activated, or the GPIbα mechano-
signaling was dysregulated. However, using cone/plate viscometer–FACS did not show 
the more agglutination of DM platelets nor more activated GPIIbIIIa. The results 
suggested either our method was not sensitive enough or the difference between DM and 
ctrl was negligible. To note, these samples were sheared for 10 min, longer than the 2 
min from Chapter 4, which could have masked any possible difference at an earlier time.  
Using DM and non-DM siblings’ samples on the same day demonstrated its 
potential of generating more consistent results, but the rarity of coming across such 
samples makes it difficult to obtain enough power. The success rate of the stenosis 
microfluidics experiments was not high due to the sensitivity of platelets to blood draw 
(how quiescent do they remain prior to the experiment), the channel imperfections, and 
particulates (from the PDMS, air, or blood tube) that occasionally come across the 
channel. Nevertheless, the results revealed a trend that corroborated our knowledge of 
increased CVD risk for diabetic patients and demand higher-throughput devices to be 
designed for the rare patient samples. Specifically, platelets’ response to gradient-shear 
was enhanced in DM compared to the control group, which largely agreed with the 
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findings from mouse injury models (Ju et al., 2018). The force loading result was to our 
surprise given the sensitivity of integrin fine-tuning its kinetics in response to force 
history as we previously reported. Maybe we could have seen a difference in probability 
of adhesion in the varied loading rates, but given the response of bond lifetimes, a 
difference in this assay alone would be hard to interpret. Ju et al. found no difference in 
integrin-fibrinogen bond lifetimes between the DM and ctrl group (data not published), 
which suggested that the platelet integrin itself may not have significantly altered in 
diabetes, but the mechano-signalling pathways were altered as shown by integrin’s 
outside-in signalling and the PI3K’s involvement. Factors such as oxidative stress, 
compressive force sensing, and the likelihood of tether formation (Ju et al., 2018; 
Maxwell et al., 2007; Nesbitt et al., 2009) may be crucial for hyperactivity of DM 
platelets. For future therapies, targeting the intracellular enzymes (PI3K, Rap1) and 
adaptors (talin) involved in the mechano-signaling may lead to better clinical outcomes 












CHAPTER 7. CONCLUSIONS AND FUTURE DIRECTIONS  
7.1 Conclusions  
We presented in this thesis the study of talin’s regulation on platelet integrin 
mechanobiology on the single-cell, single-molecule level and population (aggregate) level. 
Mechanistically, we showed how talin, through interactions with other molecules namely 
Rap1 and actin filament, regulates force-mediated integrin binding of discoid platelets. 
Discoid platelets are in a low-activation state; despite their importance in gradient shear-
induced platelet aggregation, their function was not well-examined as most studies in the 
field focused on mapping agonist-induced platelet activation pathways. With detailed 
conclusions discussed in each chapter, here we summarize the highlighted findings below: 
1. On shear-induced discoid platelet aggregation: 
o Talin-integrin and talin-Rap1 binding are crucial for gradient shear-driven 
platelet aggregation.  
o Talin interacting with the integrin MPR seems more crucial for soluble agonist-
induced and not mechano-binding induced integrin activation that happens at a 
shorter time scale  
o CalDAG-GEFI and STIM1 seemed dispensable for gradient shear-driven 
platelet aggregation. 
o Uniform shear-induced platelet agglutination and GPIIbIIIa affinity 
upregulation was mediated by GPIbα-vWF pulling. 
o Talin-integrin binding was needed for GPIIbIIIa maturation to a higher affinity 
via GPIbα mechano-signaling. 
 88 
2. On force-mediated single-platelet adhesion to fibrinogen: 
o Disruption of talin-integrin binding or talin-Rap1 binding abolished the catch 
bond between GPIIbIIIa and fibrinogen.  
o Disruption of talin-integrin binding reduced integrin engagement to the 
cytoskeleton and resulted in lower bond strength. 
o Disruption of talin-integrin binding or the ability of talin to activate the integrin 
did not alter the affinity of GPIIbIIIa to immobilized fibrinogen. 
o Talin-integrin binding appeared important for the memory (encouragement of 
future bond formation by past bonds) of single integrin adhesion to fibrinogen  
3. On the impact of diabetes on biomechanical platelet aggregation: 
o Diabetes seemed to amplify biomechanical platelet aggregation by promoting 
more GPIIbIIIa integrins to the intermediate conformational/ affinity state. 
o The difference between the DM and control group on the single molecular level 
(GPIIbIIIa) may be insignificant  
o Comparing the clotting response of DM and non-DM siblings may be more 
effective than comparing patients across demographics 
We then updated the model of GPIbα mechano-signaling by adding talin, Rap1, 
and actin as important players: GPIbα signaling prompts actin-bound talin to release from 
its autoinhibited form and be recruited to the membrane by Rap1; once activated, talin 
engages integrins, linking to them actin retrograde flow. 
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Figure 7.1. Updated model of crosstalk between GPIbα and GPIIbIIIa involving 
talin and actin. Adapted and modified from (X. F. Zhang & Cheng, 2019).  
7.2 Future directions 
The findings from this thesis raised more questions and many questions still were 
left unanswered. For the immediate follow-ups: the memory assay and cone/plate – FACS 
or the dual BFP assay could be performed with talin LR mutant platelets to complete 
delineating the roles of specific talin-integrin interactions. The thermal fluctuation assay 
that more accurately measures 2D on-rate and off-rate at zero force (W. Chen, Evans, 
McEver, & Zhu, 2008) could be used to help answer the questions about whether talin KO 
and mutants could affect force-free off-rate, and whether impingement alone could have 
primed talin to bind integrins. Adhesion frequency assay could be completed with the talin 
F1 and F1/F0 mutants to obtain a full picture of how Rap1-talin binding affects integrin 
2D kinetics. The memory effect assay could be performed with cytochalasin D-treated WT 
platelets to examine whether intact actin retrograde flow is needed for adhesion memory. 
To fully examine cytoskeletal support, other treatments such as myosin inhibitor 
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blebbistatin and ROCK inhibitor Y-27632 should be used to understand the roles of other 
cytoskeleton components on the forced binding of integrins. For the CMR analysis, varying 
the number of loading-unloading cycles could create a curve that could potentially reveal 
some difference between the WT and the talin mutant.  
To expand the study herein, talin’s role in outside-in signalling of integrins under 
flow condition could be investigated. For example, flowing talin KO, mutant, or WT 
platelets over vWF- or fibrinogen-coated chamber and examine calcium flux of arrested 
platelets over time. Cone/plate viscometer combined with Western could be a powerful 
tool to investigate further the cytoplasmic players between GPIbα and GPIIbIIIa crosstalk. 
Potentially, and based on our preliminary data (not shown), one could measure integrin β3 
tail phosphorylation, total Akt and Akt serine 437 and threonine 308 phosphorylation 
(specific phosphorylation sites may matter), total Src and phosphorylated Src, and total 
PKC and phosphorylated PKC, using FAK and phosphorylated FAK as a control (since it 
is more important for outside-in signalling).  
For the diabetic platelet aggregation study, more patients, especially sibling pairs 
could be recruited which would eliminate many confounding factors, so that a more 
definitive conclusion that diabetes exacerbates biomechanical thrombosis independent of 
agonist amplification could be reached. The conclusion was drawn from mouse platelet 
adhesion in vitro and aggregation in vivo but needs to be clearly demonstrated for human 
samples. Other aspects such as talin concentration and the occurrence of tethering in DM 
platelets compared to the control could be examined to help answering the question of why 
DM platelets seemed to have more integrins in the intermediate state. The stenosis device 
also needs innovation and improvement to increase the throughput and ease of use by 
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designing better particulate traps, multi-channel for a single run, and automatic pumping 
via, for example, a pneumatic mechanism (Szydzik et al., 2019). By presenting a striking 
difference between the DM and ctrl group, we would be better positioned to convince the 
community to focus on the biomechanical aspect of platelet activation to address the CVD 




APPENDIX A. RUNNING FREQUENCY OF PLATELET 
ADHESION TO FIBRINOGEN 
Methods: Running frequency was obtained by using the repeated BFP force clamp assay 
(platelet interacting with fibrinogen-coated bead) and continuously sliding a window of ten 
contacts to obtain adhesion frequency over contacts.  
Results: Running frequency of WT/fl platelets: each line represents one platelet. Overall, 
no clear upward or downward trend was observed, which suggested that platelet integrins 
were not getting activated over time. However, cycles of increase and decrease of adhesion 













APPENDIX B.  CONE/PLATE VISCOMETER–FACS 
REPRESENTATIVE RESULT FROM PLATELETS 
INCUBATED WITH ALB   
Methods: Washed platelets were incubated with ALB, dimeric A1, botrocetin, and JON/A-
PE, and sheared on the rheometer for 15 min at 10k s-1. Afterwards, JON/A-PE staining 
was read on FACS. Activated integrin number means % shift of JON/A-PE with resting 
baseline of 2%.  
Results: Left represents a typical result in the range of experiments without ALB; right 




APPENDIX C. REPEATS OF Q-Q PLOT OF JON/A-PE VS. FSC 
WITH OR WITHOUT ALB 
Methods: Platelet rich plasma was incubated with botrocetin (Bc) and JON/A-PE (with or 
without ALB) and sheared on the cone/plate viscometer for 2 min at 10k s-1. Afterwards, 
JON/A-PE staining was read on FACS. Data from FSC and JON/A-PE fluorescent channel 
were obtained and displayed in overlay histograms and quantile-quantile (q-q) plots.  
Results: All experiments regardless of ALB’s presence exhibited nonlinear q-q plots 
particularly on the higher quantile region, which suggested that JON/A-PE signal increase 










APPENDIX D. COMPARISON OF Β3 LA MUTANT AND WT 
CONTROL IN AGONIST ACTIVATION  
Methods: Washed platelets were incubated with JON/A-PE and 10 μM ADP or 1 U 
thrombin for 5 min, then fixed with 2% PFA and read on FACS.  
Results: Gray – resting state, orange – ADP, and green – thrombin stimulated. The number 
of activated integrin indicates the % JON/A-PE shift for the thrombin condition, using ~2% 
threshold for the resting state. Comparing the WT control (top) and β3 LA mut (bottom), 
β3 LA mut exhibited impaired integrin activation for both ADP and thrombin conditions.  
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APPENDIX E.  ADDITIONAL INFORMATION FROM THE 
CONE/PLATE UNIFORM SHEAR EXPERIMENTS  
Methods: PRP incubated with Bc and JON/A-PE in ACD buffer (chelating most but not 
all Ca2+) with (A) typical 1 mM Ca2+, (B) without extra Ca2+ added, (C)  Mg2+/EGTA, and 
(D) 1 mM Ca2+ and GsMTx4 mechanosensitive cation channel inhibitor, were uniformly 
sheared on the cone/plate viscometer for 2 min at 10k s-1 and read on FACS afterwards.  
Results: Platelets in saturated or reduced Ca2+ showed similar results, which suggested that 
not much extracellular Ca2+ was required for the agglutination, aggregation, and integrin 
activation. Platelets in Mg2+/EGTA showed normal agglutination (C) but defective JON/A-
PE staining, while GsMTx4-blocked showed normal agglutination and JON/A-PE staining 
(D). The result suggested either JON/A cannot bind GPIIbIIIa with Mg2+ and almost all 
Ca2+ chelated by EGTA, or that extracellular calcium is needed for this process, and they 
can center through other non-mechanosensitive channels. A shift in JON/A-PE binding can 
still be seen in Mg2+/EGTA condition, although the staining from the aggregate population 




































APPENDIX F.  INTEGRIN GPIIBIIIA MOLECULAR STIFFNESS  
Methods: Details of molecular stiffness analysis can be found in Y. Chen et al., 2019. 
Briefly, from BFP force clamp experiment, we can obtain molecular stiffness (regarding 
the receptor-ligand pair as spring-like materials and assuming the ligand fibrinogen does 
not change its conformations like integrins do).  
 
Results: (A) Overlay histograms of GPIIbIIIa molecular stiffness (pN/nm) of talin WA 
and WT/fl. (B) Overlay of histograms of GPIIbIIIa molecular stiffness of WT treated 
with cytochalasin D (in DMSO) and WT treated with equivalent volume DMSO. (C) 
Comparison of the mean stiffness ± SEM of the four conditions. It was implied that this 
assay could only measure the stiffness of the molecule pair itself as association of talin or 
intact cytoskeleton did not alter the result.  
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APPENDIX G. FRACTION OF LIFETIME EVENT FOR THE 
CMR AND NON-CMR ASSAYS  
Methods: On the same day with platelets from the same WT mouse, the force clamp 
lifetime assay was conducted applying cyclic mechanical reinforcement (CMR) or just 
single force clamp. The fraction of lifetime event was calculated by the number of 
established lifetimesout divided by the number of all adhesion events for each platelet.  
Results: No difference between CMR and non-CMR measurements was observed for the 
fraction of survived lifetimes, which suggested that CMR effect was not due to pre-
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